{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:39:57Z","timestamp":1793756397102,"version":"4.6.1"},"reference-count":622,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.humimm.2024.110814","type":"journal-article","created":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T14:41:31Z","timestamp":1716129691000},"page":"110814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cytokines in psoriasis: From pathogenesis to targeted therapy"],"prefix":"10.1016","volume":"85","author":[{"given":"Manahel Mahmood","family":"Alsabbagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humimm.2024.110814_b0005","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/ijd.14864","article-title":"Global burden of psoriasis - comparison of regional and global epidemiology, 1990 to 2017","volume":"59","author":"AlQassimi","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0010","unstructured":"P.C.M. van de Kerkhof, F.O. Nestl\u00e9, Psoriasis, in: J.L. Bolognia, J.V. Schaffer, L. Cerroni (Eds.) Dermatology, vol. 1, Elsevier, 2018."},{"key":"10.1016\/j.humimm.2024.110814_b0015","unstructured":"J. Gudjonsson, J.T. Elder, Psoriasis, in: L.A. Goldsmith, S. Katz, B.A. Gilchrest, A.S. Paller, D.J. Leffell, K. Wolf (Eds.) Fitzpatrick's Dermatology in General Medicine, vol. 1, McGraw Hill, 2012."},{"key":"10.1016\/j.humimm.2024.110814_b0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0025","article-title":"Cutaneous and systemic psoriasis: classifications and classification for the distinction","volume":"8","author":"Yan","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.humimm.2024.110814_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000495291","article-title":"Psoriasis: keratinocytes or immune cells - Which is the trigger?","volume":"235","author":"Benhadou","year":"2019","journal-title":"Dermatology"},{"key":"10.1016\/j.humimm.2024.110814_b0040","first-page":"173","article-title":"Histopathological aspects of psoriasis and its uncommon variants","volume":"153","author":"Ferreli","year":"2018","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5021\/ad.2015.27.1.26","article-title":"Histopathological findings are associated with the clinical types of psoriasis but not with the corresponding lesional psoriasis severity index","volume":"27","author":"Kim","year":"2015","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0050","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.clindermatol.2007.08.005","article-title":"The histopathologic spectrum of psoriasis","volume":"25","author":"Murphy","year":"2007","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1600-0625.2000.009001001.x","article-title":"Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop","volume":"9","author":"Terui","year":"2000","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0060","first-page":"162","article-title":"The role of CD4 and CD8 lymphocytes and macrophages in psoriasis vulgaris","volume":"17","author":"Cabrijan","year":"2009","journal-title":"Acta Dermatovenerol. Croat."},{"key":"10.1016\/j.humimm.2024.110814_b0065","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0923-1811(96)00517-8","article-title":"Psoriasis: comparison of immunological markers in patients with acute and remission phase","volume":"13","author":"De Pita","year":"1996","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b0070","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/000155599750011354","article-title":"Squamous cell carcinoma-related antigen (SCCr-Ag), sICAM-1 and beta 2-microglobulin are useful markers of disease activity in psoriasis","volume":"79","author":"De Pita","year":"1999","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b0075","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/BF00200540","article-title":"Immunological mechanisms involved in psoriasis","volume":"13","author":"Griffiths","year":"1992","journal-title":"Springer Semin. Immunopathol."},{"key":"10.1016\/j.humimm.2024.110814_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.1992.tb08394.x","article-title":"The immunology of psoriasis","volume":"126","author":"Baker","year":"1992","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1523-1747.ep12514646","article-title":"Characterization of skin-infiltrating lymphocytes in patients with psoriasis","volume":"96","author":"Nikaein","year":"1991","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0090","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.intimp.2015.11.005","article-title":"Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-alpha treatment in psoriasis","volume":"29","author":"Luan","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.humimm.2024.110814_b0095","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/jid.2009.399","article-title":"Circulating Th17, Th22, and Th1 cells are increased in psoriasis","volume":"130","author":"Kagami","year":"2010","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0100","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3389\/fimmu.2020.00478","article-title":"Mononuclear phagocyte activation is associated with the immunopathology of psoriasis","volume":"11","author":"Costa","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/bjd.14034","article-title":"Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris","volume":"174","author":"Chiricozzi","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0110","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2340\/00015555-1545","article-title":"Systemically elevated Th1-, Th2- and Th17-associated chemokines in psoriasis vulgaris before and after ultraviolet B treatment","volume":"93","author":"Ekman","year":"2013","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b0115","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/ATVBAHA.118.312246","article-title":"Inflammasome signaling and impaired vascular health in psoriasis","volume":"39","author":"Garshick","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.humimm.2024.110814_b0120","doi-asserted-by":"crossref","first-page":"e27365","DOI":"10.1097\/MD.0000000000027365","article-title":"CXCL10 and its related key genes as potential biomarkers for psoriasis: Evidence from bioinformatics and real-time quantitative polymerase chain reaction","volume":"100","author":"Zou","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.humimm.2024.110814_b0125","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2020.10.094","article-title":"CCL20 in psoriasis: a potential biomarker of disease severity, inflammation, and impaired vascular health","volume":"84","author":"Elnabawi","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0130","first-page":"297","article-title":"Expression of CC chemokine ligand 20 and CC chemokine receptor 6 mRNA in patients with psoriasis vulgaris","volume":"24","author":"Wu","year":"2004","journal-title":"J. Huazhong Univ. Sci. Technolog. Med. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/JID.2015.378","article-title":"Molecular phenotyping small (Asian) versus Large (Western) plaque psoriasis shows common activation of IL-17 pathway genes but different regulatory gene sets","volume":"136","author":"Kim","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0140","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaci.2003.08.049","article-title":"Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis","volume":"112","author":"Nomura","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0145","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0923-1811(02)00111-1","article-title":"CD4+ T-cells from peripheral blood of a patient with psoriasis recognize keratin 14 peptide but not 'homologous' streptococcal M-protein epitope","volume":"30","author":"Kobayashi","year":"2002","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b0150","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1034\/j.1600-0625.2002.110410.x","article-title":"Epidermal CD8+ T cells reactive with group A streptococcal antigens in chronic plaque psoriasis","volume":"11","author":"Ovigne","year":"2002","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0155","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jid.2022.10.025","article-title":"Skin IL-17A and IFN-gamma production correlate with disease severity in patients with psoriasis and streptococcal infection","volume":"143","author":"Della Bella","year":"2023","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0160","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1567-5769(01)00201-6","article-title":"Inhibition of pro-inflammatory cytokine generation by CTLA4-Ig in the skin and colon of mice adoptively transplanted with CD45RBhi CD4+ T cells correlates with suppression of psoriasis and colitis","volume":"2","author":"Davenport","year":"2002","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.humimm.2024.110814_b0165","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00403-009-0961-7","article-title":"Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab","volume":"301","author":"Bissonnette","year":"2009","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b0170","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.4049\/jimmunol.171.11.5697","article-title":"CD4+ T cell-associated pathophysiology critically depends on CD18 gene dose effects in a murine model of psoriasis","volume":"171","author":"Kess","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0175","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/1523-1747.ep12466215","article-title":"Genomic, phenotypic, and functional analyses of T cells in patients with psoriasis undergoing systemic cyclosporin A treatment","volume":"96","author":"Takashima","year":"1991","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0180","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1523-1747.1999.00749.x","volume":"113","author":"Austin","year":"1999","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0185","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/1523-1747.ep12371752","article-title":"T cells involved in psoriasis vulgaris belong to the Th1 subset","volume":"102","author":"Schlaak","year":"1994","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0190","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1172\/JCI117308","article-title":"Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines","volume":"94","author":"Nestle","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.humimm.2024.110814_b0195","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/eji.1830260916","article-title":"Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate","volume":"26","author":"de Jong","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0200","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1099\/jmm.0.003939-0","article-title":"T helper 1 to T helper 2 shift in cytokine expression: an autoregulatory process in superantigen-associated psoriasis progression?","volume":"58","author":"Jain","year":"2009","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.humimm.2024.110814_b0205","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/1523-1747.ep12468941","article-title":"A potential role for superantigens in the pathogenesis of psoriasis","volume":"100","author":"Leung","year":"1993","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0210","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0190-9622(92)70203-R","article-title":"Epidermal dendritic cells in psoriasis possess a phenotype associated with antigen presentation: in situ expression of beta 2-integrins","volume":"27","author":"McGregor","year":"1992","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0215","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clim.2009.11.008","article-title":"Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity","volume":"135","author":"Zhang","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0220","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2133.2010.09742.x","article-title":"Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris","volume":"163","author":"Yan","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0225","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/sji.12404","article-title":"Characterization of Th17 and FoxP3(+) Treg cells in paediatric psoriasis patients","volume":"83","author":"Zhang","year":"2016","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0230","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s12013-014-0230-z","article-title":"Disruption of circulating CD4+ T-lymphocyte subpopulations in psoriasis patients is ameliorated by narrow-band UVB therapy","volume":"71","author":"Wang","year":"2015","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.humimm.2024.110814_b0235","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1172\/JCI34916","article-title":"TGF-beta-dependent suppressive function of Tregs requires wild-type levels of CD18 in a mouse model of psoriasis","volume":"118","author":"Wang","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.humimm.2024.110814_b0240","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clim.2015.10.004","article-title":"Natural killer cells from psoriasis vulgaris patients have reduced levels of cytotoxicity associated degranulation and cytokine production","volume":"177","author":"Dunphy","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0245","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/j.1365-2133.2010.09990.x","article-title":"Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris","volume":"163","author":"Anderson","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0250","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00011-019-01238-8","article-title":"Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors","volume":"68","author":"Cataldi","year":"2019","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.humimm.2024.110814_b0255","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.18632\/oncotarget.22260","article-title":"Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis","volume":"9","author":"Bai","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.humimm.2024.110814_b0260","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3389\/fimmu.2019.01865","article-title":"IL-21 Induces an Imbalance of Th17\/Treg Cells in Moderate-to-Severe Plaque Psoriasis Patients","volume":"10","author":"Shi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0265","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s11596-014-1322-0","article-title":"Analysis of Th1\/Th2 response pattern for erythrodermic psoriasis","volume":"34","author":"Zhang","year":"2014","journal-title":"J. Huazhong Univ. Sci. Technolog. Med. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b0270","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4103\/ijdvl.IJDVL_471_17","article-title":"Is there a correlation of serum and tissue T helper-1 and -2 cytokine profiles with psoriasis activity and severity? A cross-sectional study","volume":"84","author":"Khandpur","year":"2018","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"10.1016\/j.humimm.2024.110814_b0275","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/268257","article-title":"Serum levels of LL-37 and inflammatory cytokines in plaque and guttate psoriasis","volume":"2014","author":"Hwang","year":"2014","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.humimm.2024.110814_b0280","doi-asserted-by":"crossref","first-page":"738","DOI":"10.5021\/ad.2015.27.6.738","article-title":"Tissue and serum inflammatory cytokine levels in Korean psoriasis patients: a comparison between plaque and guttate psoriasis","volume":"27","author":"Roh","year":"2015","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0285","first-page":"208","article-title":"Polymorphisms in T helper 1 proinflammatory cytokine genes and the risk of psoriasis in a South Indian Tamil cohort","volume":"15","author":"Indhumathi","year":"2017","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/j.humimm.2024.110814_b0290","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/MI.2005.273","article-title":"Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity","volume":"2005","author":"Arican","year":"2005","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.humimm.2024.110814_b0295","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/09629350310001619753","article-title":"Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity","volume":"12","author":"Jacob","year":"2003","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.humimm.2024.110814_b0300","doi-asserted-by":"crossref","first-page":"858","DOI":"10.5114\/ada.2021.110109","article-title":"Evaluation of cytokine gene expression in psoriasis","volume":"38","author":"Divyapriya","year":"2021","journal-title":"Postepy Dermatol. Alergol."},{"key":"10.1016\/j.humimm.2024.110814_b0305","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5455\/medarh.2018.72.410-413","article-title":"Serum concentrations of interferon gamma (IFN-gamma) in patients with psoriasis: correlation with clinical type and severity of the disease","volume":"72","author":"Kurtovic","year":"2018","journal-title":"Med. Arch."},{"key":"10.1016\/j.humimm.2024.110814_b0310","first-page":"163","article-title":"Serum interferon-gamma is a psoriasis severity and prognostic marker","volume":"84","author":"Abdallah","year":"2009","journal-title":"Cutis"},{"key":"10.1016\/j.humimm.2024.110814_b0315","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s004030050299","article-title":"An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis","volume":"290","author":"Terajima","year":"1998","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b0320","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.0007-0963.2004.05891.x","article-title":"Psoriasis genomics: analysis of proinflammatory (type 1) gene expression in large plaque (Western) and small plaque (Asian) psoriasis vulgaris","volume":"150","author":"Lew","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0325","first-page":"294","article-title":"The expression of interleukin-17, interferon-gamma, and macrophage inflammatory protein-3 alpha mRNA in patients with psoriasis vulgaris","volume":"24","author":"Li","year":"2004","journal-title":"J. Huazhong Univ. Sci. Technolog. Med. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b0330","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1152\/physiolgenomics.00157.2002","article-title":"Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array","volume":"13","author":"Zhou","year":"2003","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.humimm.2024.110814_b0335","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clinbiochem.2005.11.008","article-title":"The role of interleukin-12 in the pathogenesis of psoriasis","volume":"39","author":"Shaker","year":"2006","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.humimm.2024.110814_b0340","doi-asserted-by":"crossref","first-page":"635","DOI":"10.13075\/ijomeh.1896.01513","article-title":"Analysis of molecular markers as IL-12, IL-22 and IFN-gamma in correlation with a clinical course in patients with psoriasis","volume":"33","author":"Kutwin","year":"2020","journal-title":"Int. J. Occup. Med. Environ. Health"},{"key":"10.1016\/j.humimm.2024.110814_b0345","doi-asserted-by":"crossref","first-page":"e10247","DOI":"10.1371\/journal.pone.0010247","article-title":"Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA)","volume":"5","author":"Suarez-Farinas","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.humimm.2024.110814_b0350","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/phpp.12790","article-title":"Influence of narrow-band ultraviolet B therapy on sirtuin 1 expression in lesional skin of patients with chronic plaque psoriasis: Relation to clinical improvement and interferon-gamma expression","volume":"38","author":"Eid","year":"2022","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"10.1016\/j.humimm.2024.110814_b0355","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0360","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1038\/jid.2010.166","article-title":"Effective narrow-band UVB radiation therapy suppresses the IL-23\/IL-17 axis in normalized psoriasis plaques","volume":"130","author":"Johnson-Huang","year":"2010","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0365","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.0906-6705.2004.00246.x","article-title":"Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers \u2013 IL-12, IL-18 and IL-23","volume":"13","author":"Piskin","year":"2004","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0370","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9030745","article-title":"Enhanced Inflammation and Nitrosative Stress in the Saliva and Plasma of Patients with Plaque Psoriasis","volume":"9","author":"Skutnik-Radziszewska","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.humimm.2024.110814_b0375","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ad.2009.07.021","article-title":"Production of interleukin-8 by circulating CLA+ T cells with skin tropism in patients with psoriasis and in healthy controls","volume":"101","author":"Ferran","year":"2010","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.humimm.2024.110814_b0380","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.1523-1747.2000.00919.x","article-title":"Skin CD4+ T cells produce interferon-gamma in vitro in response to streptococcal antigens in chronic plaque psoriasis","volume":"114","author":"Brown","year":"2000","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0385","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1034\/j.1600-0625.2001.010003168.x","article-title":"Epidermal CD8+ T cells in chronic plaque psoriasis are Tc1 cells producing heterogeneous levels of interferon-gamma","volume":"10","author":"Ovigne","year":"2001","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0390","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1189\/JLB.0109046","article-title":"IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines","volume":"86","author":"Ortega","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.humimm.2024.110814_b0395","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jdermsci.2018.07.001","article-title":"The distinct role and regulatory mechanism of IL-17 and IFN-gamma in the initiation and development of plaque vs guttate psoriasis","volume":"92","author":"Yan","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b0400","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1365-4362.1999.00622.x","article-title":"Cytokines in psoriasis","volume":"38","author":"Bonifati","year":"1999","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0405","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/bjd.12812","article-title":"Interferon-gamma\/CCR5 expression in invariant natural killer T cells and CCL5 expression in capillary veins of dermal papillae correlate with development of psoriasis vulgaris","volume":"170","author":"Kono","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0410","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.4049\/jimmunol.179.5.3249","article-title":"Genetic control directed toward spontaneous IFN-alpha\/IFN-beta responses and downstream IFN-gamma expression influences the pathogenesis of a murine psoriasis-like skin disease","volume":"179","author":"Arakura","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.humimm.2024.110814_b0415","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00403-008-0874-x","article-title":"Is there a role for mast cells in psoriasis?","volume":"300","author":"Harvima","year":"2008","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b0420","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/labinvest.2012.69","article-title":"Pathological crosstalk in vitro between T lymphocytes and lesional keratinocytes in psoriasis: necessity of direct cell-to-cell contact","volume":"92","author":"Martin","year":"2012","journal-title":"Lab. Invest."},{"key":"10.1016\/j.humimm.2024.110814_b0425","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jdermsci.2005.01.001","article-title":"HLA DR B1*04, *07-restricted epitopes on Keratin 17 for autoreactive T cells in psoriasis","volume":"38","author":"Shen","year":"2005","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b0430","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/archderm.1990.01670270083013","article-title":"Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations","volume":"126","author":"Fierlbeck","year":"1990","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0435","doi-asserted-by":"crossref","first-page":"138S","DOI":"10.1111\/1523-1747.ep12875040","article-title":"Treatment of psoriasis and psoriatic arthritis with interferon gamma","volume":"95","author":"Fierlbeck","year":"1990","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0440","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1432-1033.1995.tb20370.x","article-title":"Transcriptional activation of psoriasis-associated cytokeratin K17 by interferon-gamma. Analysis of gamma-interferon activation sites","volume":"227","author":"Vogel","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.humimm.2024.110814_b0445","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000081685","article-title":"Interferon-gamma-dependent in vitro model for the putative keratin 17 autoimmune loop in psoriasis: exploration of pharmaco- and gene-therapeutic effects","volume":"18","author":"Bockelmann","year":"2005","journal-title":"Skin Pharmacol. Physiol."},{"key":"10.1016\/j.humimm.2024.110814_b0450","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaad.2006.07.034","article-title":"Keratin 17\/interferon-gamma autoimmune loop as a vicious circle driving psoriasis pathogenesis","volume":"56","author":"Bonnekoh","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.humimm.2024.110814_b0455","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1096-9896(199902)187:3<358::AID-PATH253>3.0.CO;2-8","article-title":"IL-1 beta and IFN-gamma induce the regenerative epidermal phenotype of psoriasis in the transwell skin organ culture system. IFN-gamma up-regulates the expression of keratin 17 and keratinocyte transglutaminase via endogenous IL-1 production","volume":"187","author":"Wei","year":"1999","journal-title":"J. Pathol."},{"key":"10.1016\/j.humimm.2024.110814_b0460","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/jid.2013.440","article-title":"The adverse effect of IFN gamma on stratum corneum structure and function in psoriasis and atopic dermatitis","volume":"134","author":"Feingold","year":"2014","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0465","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/jid.2013.364","article-title":"Interferon-gamma decreases ceramides with long-chain fatty acids: possible involvement in atopic dermatitis and psoriasis","volume":"134","author":"Tawada","year":"2014","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0470","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/exd.14431","article-title":"Decrease of ceramides with long-chain fatty acids in psoriasis: Possible inhibitory effect of interferon gamma on chain elongation","volume":"31","author":"Kim","year":"2022","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0475","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.4049\/jimmunol.181.7.4733","article-title":"Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis","volume":"181","author":"Kryczek","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0480","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/gene.2009.11","article-title":"Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis","volume":"10","author":"Elder","year":"2009","journal-title":"Genes Immun."},{"key":"10.1016\/j.humimm.2024.110814_b0485","doi-asserted-by":"crossref","first-page":"555","DOI":"10.4049\/jimmunol.2001310","article-title":"IFN-gamma drives human monocyte differentiation into highly proinflammatory macrophages that resemble a phenotype relevant to psoriasis","volume":"207","author":"Luque-Martin","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0490","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00109-009-0457-0","article-title":"IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not","volume":"87","author":"Wolk","year":"2009","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.humimm.2024.110814_b0495","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0140-6736(86)90450-2","article-title":"Gamma interferon and psoriasis","volume":"2","author":"Schulze","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.humimm.2024.110814_b0500","first-page":"80","article-title":"Arthritis in patients with psoriasis treated with gamma-interferon","volume":"19","author":"O'Connell","year":"1992","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.humimm.2024.110814_b0505","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/archderm.1987.01660360061013","article-title":"Use of recombinant interferon gamma administered intramuscularly for the treatment of psoriasis","volume":"123","author":"Morhenn","year":"1987","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0510","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jaci.2014.05.046","article-title":"Humanized anti-IFN-gamma (HuZAF) in the treatment of psoriasis","volume":"135","author":"Harden","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0515","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1365-2133.2012.11038.x","article-title":"A comparison of serum inflammatory cytokines according to phenotype in patients with psoriasis","volume":"167","author":"Choe","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0520","first-page":"169","article-title":"Evaluation of cytokine serum levels in patients with plaque-type psoriasis","volume":"25","author":"Roussaki-Schulze","year":"2005","journal-title":"Int. J. Clin. Pharmacol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b0525","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-4632.2004.02082.x","article-title":"Serum levels of proinflammatory cytokines in psoriasis patients from Saudi Arabia","volume":"44","author":"Abanmi","year":"2005","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0530","doi-asserted-by":"crossref","first-page":"81767","DOI":"10.1155\/MI\/2006\/81767","article-title":"Interleukin 6 and 8 levels in plasma and fibroblast cultures in psoriasis","volume":"2006","author":"Zalewska","year":"2006","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.humimm.2024.110814_b0535","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1600-0625.1996.tb00137.x","article-title":"The chemotactic activity of T-lymphocytes in response to interleukin 8 is significantly decreased in patients with psoriasis and atopic dermatitis","volume":"5","author":"Zheng","year":"1996","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0540","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2340\/0001555571403406","article-title":"Production of interleukin-2 by mononuclear cells in vitro in patients with atopic dermatitis and psoriasis. Comparison with serum interleukin-2 receptor levels","volume":"71","author":"Kapp","year":"1991","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b0545","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2133.1988.tb03491.x","article-title":"Elevated levels of interleukin 2 receptor in sera of patients with atopic dermatitis and psoriasis","volume":"119","author":"Kapp","year":"1988","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0550","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2230.1991.tb00402.x","article-title":"Effect of UVB plus tar therapy on serum levels of interleukin-2 receptors in patients with psoriasis","volume":"16","author":"Betti","year":"1991","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0555","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/1043-4666(90)90045-U","article-title":"Cytokines in skin lesions of psoriasis","volume":"2","author":"Gearing","year":"1990","journal-title":"Cytokine"},{"key":"10.1016\/j.humimm.2024.110814_b0560","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1001\/archderm.1988.01670120027005","article-title":"Interleukin 2 and psoriasis","volume":"124","author":"Lee","year":"1988","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0565","doi-asserted-by":"crossref","first-page":"25","DOI":"10.26574\/maedica.2018.13.1.25","article-title":"Treatment Effects upon Prolactin and Soluble Receptor of Interleukin-2 in Psoriatic Patients","volume":"13","author":"Botezatu","year":"2018","journal-title":"Maedica (Bucur)"},{"key":"10.1016\/j.humimm.2024.110814_b0570","first-page":"61","article-title":"The functional properties of interleukins in psoriasis","author":"Kozin","year":"1989","journal-title":"Vestn. Dermatol. Venerol."},{"key":"10.1016\/j.humimm.2024.110814_b0575","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2249.1991.tb05721.x","article-title":"Soluble IL-2 receptor and CD25 cells in psoriasis: effects of cyclosporin A and PUVA therapy","volume":"85","author":"Duncan","year":"1991","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0580","first-page":"166","article-title":"Influence of systemic cyclosporin A on interleukin-2 and epidermal growth factor receptor expression in psoriatic skin lesions","volume":"78","author":"Horroccks","year":"1989","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0585","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1177\/0300060514539280","article-title":"Serum concentrations of interleukin-2 and tumour necrosis factor-alpha under cyclosporine versus acitretin treatment in plaque-type psoriasis","volume":"42","author":"Akcali","year":"2014","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.humimm.2024.110814_b0590","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2340\/0001555570264266","article-title":"Serum-soluble interleukin 2 receptor in psoriasis. Failure to reflect clinical improvement","volume":"70","author":"Kemmett","year":"1990","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b0595","doi-asserted-by":"crossref","first-page":"64727","DOI":"10.1155\/2007\/64727","article-title":"Mediators of pruritus in psoriasis","volume":"2007","author":"Reich","year":"2007","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.humimm.2024.110814_b0600","first-page":"166","article-title":"T-lymphocyte chemotaxis to IL-8 in patients with psoriasis in vitro","volume":"111","author":"Zheng","year":"1998","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.humimm.2024.110814_b0605","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/jaut.1999.0343","article-title":"CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry","volume":"14","author":"Ferenczi","year":"2000","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.humimm.2024.110814_b0610","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s10753-023-01883-6","article-title":"Low-dose Interleukin-2 for psoriasis therapy based on the regulation of Th17\/Treg cell balance in peripheral blood","volume":"46","author":"Qiao","year":"2023","journal-title":"Inflammation"},{"key":"10.1016\/j.humimm.2024.110814_b0615","first-page":"21","article-title":"Molecular and cellular mechanisms of itch in psoriasis","author":"Komiya","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b0620","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1046\/j.1365-2133.2003.05586.x","article-title":"Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors","volume":"149","author":"Nakamura","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0625","first-page":"1546","article-title":"Targeting interleukin-2 as a treatment for psoriasis","volume":"2","author":"Salim","year":"2001","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.humimm.2024.110814_b0630","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2230.2000.00612.x","article-title":"Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody","volume":"25","author":"Owen","year":"2000","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0635","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1067\/mjd.2000.106515","article-title":"Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis","volume":"43","author":"Krueger","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0640","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1365-4632.2008.03677.x","article-title":"Serum levels of the pro-inflammatory cytokine interleukin-12 and the anti-inflammatory cytokine interleukin-10 in patients with psoriasis treated by the Goeckerman regimen","volume":"47","author":"Borska","year":"2008","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0645","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000471798","article-title":"New Interleukins in Psoriasis and Psoriatic Arthritis Patients: The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions","volume":"233","author":"Li","year":"2017","journal-title":"Dermatology"},{"key":"10.1016\/j.humimm.2024.110814_b0650","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/cei.13370","article-title":"Evidence for a role of autoinflammation in early-phase psoriasis","volume":"198","author":"Fanoni","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0655","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000018213","article-title":"Interleukin 12 and psoriasis","volume":"199","author":"de Rie","year":"1999","journal-title":"Dermatology"},{"key":"10.1016\/j.humimm.2024.110814_b0660","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jdermsci.2016.09.019","article-title":"Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway","volume":"85","author":"Bissonnette","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b0665","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaci.2021.09.035","article-title":"Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis","volume":"149","author":"Baum","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0670","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020858","article-title":"Molecular aspects of pruritus pathogenesis in psoriasis","volume":"22","author":"Jaworecka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b0675","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1046\/j.1523-1747.1998.00446.x","article-title":"Expression of interleukin-12 is increased in psoriatic skin","volume":"111","author":"Yawalkar","year":"1998","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0680","first-page":"86","article-title":"A study on the expression of interleukin (IL)-10 and IL-12 P35, P40 mRNA in the psoriatic lesions","volume":"21","author":"Cheng","year":"2001","journal-title":"J. Tongji Med. Univ."},{"key":"10.1016\/j.humimm.2024.110814_b0685","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/1753425919852156","article-title":"The contribution of IL-17 to the development of autoimmunity in psoriasis","volume":"25","author":"Furue","year":"2019","journal-title":"Innate Immun."},{"key":"10.1016\/j.humimm.2024.110814_b0690","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/exd.14566","article-title":"Suppression of IL-12\/IL-23 p40 subunit in the skin and blood of psoriasis patients by Tofacitinib is dependent on active interferon-gamma signaling in dendritic cells: Implications for the treatment of psoriasis and interferon-driven diseases","volume":"31","author":"Vincken","year":"2022","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0695","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1365-2133.2006.07180.x","article-title":"Interleukin 12 production by monocytes from patients with psoriasis and its inhibition by ciclosporin A","volume":"154","author":"Tada","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0700","doi-asserted-by":"crossref","first-page":"7480","DOI":"10.4049\/jimmunol.162.12.7480","article-title":"IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder","volume":"162","author":"Hong","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0705","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/JLB.3MA0320-363RR","article-title":"Stress aggravates and prolongs imiquimod-induced psoriasis-like epidermal hyperplasis and IL-1beta\/IL-23p40 production","volume":"108","author":"Wang","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.humimm.2024.110814_b0710","doi-asserted-by":"crossref","first-page":"eabg9012","DOI":"10.1126\/sciimmunol.abg9012","article-title":"IL-12 regulates type 3 immunity through interfollicular keratinocytes in psoriasiform inflammation","volume":"6","author":"Zwicky","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0715","doi-asserted-by":"crossref","first-page":"13466","DOI":"10.1038\/ncomms13466","article-title":"IL-12 protects from psoriasiform skin inflammation","volume":"7","author":"Kulig","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.humimm.2024.110814_b0720","doi-asserted-by":"crossref","first-page":"336","DOI":"10.5114\/ada.2016.62838","article-title":"Are interleukin-15 and -22 a new pathogenic factor in pustular palmoplantar psoriasis?","volume":"33","author":"Lesiak","year":"2016","journal-title":"Postepy Dermatol. Alergol."},{"key":"10.1016\/j.humimm.2024.110814_b0725","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/exd.14113","article-title":"IL-15 and IL-23 synergize to trigger Th17 response by CLA(+) T cells in psoriasis","volume":"29","author":"de Jesus-Gil","year":"2020","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0730","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.4049\/jimmunol.165.4.2240","article-title":"Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis?","volume":"165","author":"Ruckert","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0735","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1172\/JCI200318986","article-title":"Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model","volume":"112","author":"Villadsen","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.humimm.2024.110814_b0740","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1002\/eji.201343801","article-title":"TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis","volume":"43","author":"Flutter","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0745","first-page":"3188","article-title":"Interleukin-21 is associated with the severity of psoriasis vulgaris through promoting CD4+ T cells to differentiate into Th17 cells","volume":"8","author":"Wang","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.humimm.2024.110814_b0750","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5021\/ad.2017.29.1.108","article-title":"Are Peripheral Natural Killer Cells and Interleukin-21 Interrelated in Psoriasis Pathogenesis?","volume":"29","author":"Hegab","year":"2017","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0755","doi-asserted-by":"crossref","first-page":"e23375","DOI":"10.1096\/fj.202201709RRRR","article-title":"IL-21 promoting angiogenesis contributes to the development of psoriasis","volume":"38","author":"Han","year":"2024","journal-title":"FASEB J."},{"key":"10.1016\/j.humimm.2024.110814_b0760","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/nm.1995","article-title":"Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis","volume":"15","author":"Caruso","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.humimm.2024.110814_b0765","doi-asserted-by":"crossref","first-page":"19295","DOI":"10.1038\/srep19295","article-title":"Transcriptome profiling unveils the role of cholesterol in IL-17A signaling in psoriasis","volume":"6","author":"Varshney","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.humimm.2024.110814_b0770","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2133.2012.10899.x","article-title":"Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis","volume":"167","author":"He","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0775","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/819149","article-title":"IL-17A, IL-22, IL-6, and IL-21 serum levels in plaque-type psoriasis in Brazilian patients","volume":"2015","author":"de Oliveira","year":"2015","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.humimm.2024.110814_b0780","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/exd.13481","article-title":"Interleukin-21 receptor signalling is not critically required for imiquimod-induced psoriasiform dermatitis in mice","volume":"27","author":"Kim","year":"2018","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0785","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/ced.12845","article-title":"Circulating T-helper 17 cells and associated cytokines in psoriasis","volume":"41","author":"Chhabra","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0790","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.3906\/sag-1904-48","article-title":"Evaluation of interleukin-23 receptor (IL-23R) gene polymorphisms and serum IL-23 levels in patients with psoriasis","volume":"49","author":"Filiz","year":"2019","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.humimm.2024.110814_b0795","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/1203475415584503","article-title":"IL-17A, IL-22, and IL-23 as markers of psoriasis activity: a cross-sectional, hospital-based study","volume":"19","author":"Fotiadou","year":"2015","journal-title":"J. Cutan Med. Surg."},{"key":"10.1016\/j.humimm.2024.110814_b0800","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5114\/ada.2018.77665","article-title":"The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor alpha in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis","volume":"35","author":"Pirowska","year":"2018","journal-title":"Postepy Dermatol. Alergol."},{"key":"10.1016\/j.humimm.2024.110814_b0805","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1365-2133.2010.09992.x","article-title":"Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-alpha levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy","volume":"163","author":"Coimbra","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0810","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1097\/CM9.0000000000001227","article-title":"Comparison between guttate and plaque psoriasis in terms of serum inflammatory cytokines and antimicrobial peptides","volume":"133","author":"Liu","year":"2020","journal-title":"Chin Med. J. (Engl.)"},{"key":"10.1016\/j.humimm.2024.110814_b0815","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.4049\/jimmunol.1001538","article-title":"Cutting edge: a critical functional role for IL-23 in psoriasis","volume":"185","author":"Tonel","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0820","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/archdermatol.2010.168","article-title":"Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis","volume":"146","author":"Lillis","year":"2010","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0825","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11596-007-0329-1","article-title":"Expression of Th17 cytokines in skin lesions of patients with psoriasis","volume":"27","author":"Li","year":"2007","journal-title":"J. Huazhong Univ. Sci. Technolog. Med. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b0830","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.humimm.2024.110814_b0835","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdermsci.2009.01.003","article-title":"Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis","volume":"54","author":"Yawalkar","year":"2009","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b0840","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jaci.2014.04.022","article-title":"Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis","volume":"134","author":"Volpe","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0845","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/exd.14071","article-title":"Role of neuroimmune circuits and pruritus in psoriasis","volume":"29","author":"Ayasse","year":"2020","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0850","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.2147\/DMSO.S405374","article-title":"Insulin stimulates IL-23 expression in human adipocytes: a possible explanation for the higher prevalence of psoriasis in obesity","volume":"16","author":"Di Vincenzo","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.humimm.2024.110814_b0855","doi-asserted-by":"crossref","first-page":"8259","DOI":"10.1038\/s41598-020-65269-6","article-title":"Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice","volume":"10","author":"Chen","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.humimm.2024.110814_b0860","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.humimm.2024.110814_b0865","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s13238-018-0505-z","article-title":"IL-23-induced macrophage polarization and its pathological roles in mice with imiquimod-induced psoriasis","volume":"9","author":"Hou","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.humimm.2024.110814_b0870","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1038\/s41598-019-41655-7","article-title":"Monocytes\/Macrophages play a pathogenic role in IL-23 mediated psoriasis-like skin inflammation","volume":"9","author":"Wang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.humimm.2024.110814_b0875","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.jid.2020.03.973","article-title":"Immune modulation of monocytes dampens the IL-17(+) gammadelta T cell response and associated psoriasis pathology in mice","volume":"140","author":"Pinget","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0880","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1172\/JCI37378","article-title":"CCR6 is required for IL-23-induced psoriasis-like inflammation in mice","volume":"119","author":"Hedrick","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.humimm.2024.110814_b0885","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/jid.2014.98","article-title":"IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing gammadelta T cells","volume":"134","author":"Yoshiki","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0890","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.4049\/jimmunol.176.3.1908","article-title":"In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin","volume":"176","author":"Piskin","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0895","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.4049\/jimmunol.1000148","article-title":"Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model","volume":"186","author":"Nakajima","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0900","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jid.2018.09.037","article-title":"Biological effects of IL-26 on T cell-mediated skin inflammation, including psoriasis","volume":"139","author":"Itoh","year":"2019","journal-title":"J. Invest Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0905","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1038\/s41467-023-39484-4","article-title":"Differentiation of IL-26(+) T(H)17 intermediates into IL-17A producers via epithelial crosstalk in psoriasis","volume":"14","author":"Fries","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.humimm.2024.110814_b0910","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/467541","article-title":"Serum levels of TNF-alpha, IL-12\/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity","volume":"2014","author":"Kyriakou","year":"2014","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b0915","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/ced.14335","article-title":"Interleukin-9 serves as a key link between systemic inflammation and angiogenesis in psoriasis","volume":"46","author":"Midde","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0920","doi-asserted-by":"crossref","first-page":"e14545","DOI":"10.1111\/ijcp.14545","article-title":"Serum galectin-3 levels in patients with psoriasis","volume":"75","author":"Hayran","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.humimm.2024.110814_b0925","doi-asserted-by":"crossref","first-page":"689","DOI":"10.34172\/aim.2021.99","article-title":"Serum expression of IL-33 and ST2 in patients with psoriasis vulgaris","volume":"24","author":"Dong","year":"2021","journal-title":"Arch. Iran Med."},{"key":"10.1016\/j.humimm.2024.110814_b0930","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1590\/abd1806-4841.20186123","article-title":"The potential role of Th17 lymphocytes in patients with psoriasis","volume":"93","author":"Mansouri","year":"2018","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0935","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00403-012-1229-1","article-title":"Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis","volume":"304","author":"Yilmaz","year":"2012","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b0940","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/ced.13033","article-title":"Association between plasma interleukin-17 levels and risk of psoriasis: a meta-analysis","volume":"42","author":"Zhou","year":"2017","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0945","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jdermsci.2010.03.018","article-title":"Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy","volume":"58","author":"Lo","year":"2010","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b0950","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1111\/jocd.15299","article-title":"Serum immunoglobulin E and Interleukin-17 levels in patients with chronic plaque psoriasis: a case-control study","volume":"21","author":"Nassar","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0955","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6092808","article-title":"Evaluation of serum proinflammatory cytokine IL-17A and tight junction protein Claudin-1 in psoriasis","volume":"2022","author":"Xu","year":"2022","journal-title":"Contrast Media Mol. Imaging"},{"key":"10.1016\/j.humimm.2024.110814_b0960","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/bjd.20090","article-title":"Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways","volume":"185","author":"Tollenaere","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0965","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"beta-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0970","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells","volume":"128","author":"Lowes","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b0975","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1468-3083.2011.04345.x","article-title":"Narrowband ultraviolet B phototherapy decreased the serum IL-17E level in a patient with psoriasis vulgaris","volume":"26","author":"Otsuka","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b0980","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10875-008-9233-0","article-title":"Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial","volume":"29","author":"Caproni","year":"2009","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b0985","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jaci.2009.08.046","article-title":"Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes","volume":"124","author":"Zaba","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"issue":"Suppl 1","key":"10.1016\/j.humimm.2024.110814_b0990","first-page":"S73","article-title":"Effects of TNF-alpha inhibitors on circulating Th17 cells in patients affected by severe psoriasis","volume":"75","author":"Piaserico","year":"2014","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.humimm.2024.110814_b0995","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jdermsci.2014.11.008","article-title":"TNF inhibitors directly target Th17 cells via attenuation of autonomous TNF\/TNFR2 signalling in psoriasis","volume":"77","author":"Shiga","year":"2015","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b1000","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/jid.2008.294","article-title":"Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis","volume":"129","author":"Watanabe","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/exd.13182","article-title":"IL-17F regulates psoriasis-associated genes through IkappaBzeta","volume":"26","author":"Bertelsen","year":"2017","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1010","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1015","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/jid.2012.456","article-title":"CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-gamma, IL-13, IL-17, and IL-22","volume":"133","author":"Hijnen","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1020","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4049\/jimmunol.1100123","article-title":"Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis","volume":"187","author":"Lin","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1025","doi-asserted-by":"crossref","first-page":"e14108","DOI":"10.1371\/journal.pone.0014108","article-title":"Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis","volume":"5","author":"Res","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.humimm.2024.110814_b1030","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00403-014-1488-0","article-title":"Innate immune cells express IL-17A\/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis","volume":"306","author":"Kakeda","year":"2014","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b1035","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jid.2019.10.010","article-title":"Enrichment of polyfunctional IL-17-producing T cells in paradoxical psoriasis skin lesions","volume":"140","author":"Moran","year":"2020","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1040","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1111\/bjd.15533","article-title":"Interleukin (IL)-17A and IL-22-producing neutrophils in psoriatic skin","volume":"177","author":"Dyring-Andersen","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1045","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1111\/1346-8138.13807","article-title":"Neutrophils are not the dominant interleukin-17 producer in psoriasis","volume":"44","author":"Yamanaka","year":"2017","journal-title":"J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1050","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1038\/jid.2014.261","article-title":"The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells","volume":"134","author":"Teunissen","year":"2014","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1055","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.4049\/jimmunol.1101817","article-title":"Epidermal CCR6+ gammadelta T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis","volume":"187","author":"Mabuchi","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1060","doi-asserted-by":"crossref","first-page":"e15026","DOI":"10.1111\/exd.15026","article-title":"Increased neutrophil-derived IL-17A identified in generalized pustular psoriasis","volume":"33","author":"Lan","year":"2024","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1065","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.humimm.2024.110814_b1070","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1995-7645(14)60046-8","article-title":"Correlation of expression of STAT3, VEGF and differentiation of Th17 cells in psoriasis vulgaris of guinea pig","volume":"7","author":"Zheng","year":"2014","journal-title":"Asian Pac. J. Trop. Med."},{"key":"10.1016\/j.humimm.2024.110814_b1075","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jaad.2017.05.017","article-title":"Skin-infiltrating, interleukin-22-producing T cells differentiate pediatric psoriasis from adult psoriasis","volume":"77","author":"Cordoro","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1080","article-title":"Mast cells express IL17A, IL17F and RORC, are activated and persist with IL-17 production in resolved skin of patients with chronic plaque-type psoriasis","author":"Benezeder","year":"2024","journal-title":"Res Sq"},{"key":"10.1016\/j.humimm.2024.110814_b1085","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjd.17748","article-title":"CD8 resident memory T cells with interleukin 17A-producing potential are accumulated in disease-naive nonlesional sites of psoriasis possibly in correlation with disease duration","volume":"181","author":"Vo","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdermsci.2019.06.002","article-title":"Significance of IL-17A-producing CD8(+)CD103(+) skin resident memory T cells in psoriasis lesion and their possible relationship to clinical course","volume":"95","author":"Kurihara","year":"2019","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b1095","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","article-title":"Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis","volume":"192","author":"Cheuk","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1100","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1172\/JCI93396","article-title":"Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing alphabeta T cell clones","volume":"127","author":"Matos","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.humimm.2024.110814_b1105","doi-asserted-by":"crossref","first-page":"11251","DOI":"10.3390\/ijerph182111251","article-title":"Assessment of the tissue resident memory cells in lesional skin of patients with psoriasis and in healthy skin of healthy volunteers","volume":"18","author":"Kasprowicz-Furmanczyk","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.humimm.2024.110814_b1110","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/exd.12691","article-title":"Obesity exacerbates imiquimod-induced psoriasis-like epidermal hyperplasia and interleukin-17 and interleukin-22 production in mice","volume":"24","author":"Kanemaru","year":"2015","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1115","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0625.2010.01224.x","article-title":"Tobacco smoke is related to Th17 generation with clinical implications for psoriasis patients","volume":"20","author":"Torii","year":"2011","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1120","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jid.2018.11.021","article-title":"Neutrophil extracellular traps induce human Th17 cells: effect of psoriasis-associated TRAF3IP2 genotype","volume":"139","author":"Lambert","year":"2019","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1125","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jid.2019.04.020","article-title":"Psoriasis caught in the NET","volume":"139","author":"Di Domizio","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1130","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jid.2017.08.048","article-title":"Microbe-dependent induction of IL-9 by CLA(+) T cells in psoriasis and relationship with IL-17A","volume":"138","author":"Ruiz-Romeu","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1135","doi-asserted-by":"crossref","first-page":"e51752","DOI":"10.1371\/journal.pone.0051752","article-title":"Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis","volume":"8","author":"Singh","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.humimm.2024.110814_b1140","doi-asserted-by":"crossref","first-page":"1256133","DOI":"10.3389\/fimmu.2023.1256133","article-title":"IL-17A-driven psoriasis is critically dependent on IL-36 signaling","volume":"14","author":"Fischer","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1145","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/jid.2011.139","article-title":"Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin","volume":"131","author":"Bovenschen","year":"2011","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1150","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.jid.2016.04.035","article-title":"Cross-disease transcriptomics: unique IL-17A signaling in psoriasis lesions and an autoimmune PBMC signature","volume":"136","author":"Swindell","year":"2016","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1155","doi-asserted-by":"crossref","first-page":"15631","DOI":"10.1038\/s41598-017-15892-7","article-title":"The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function","volume":"7","author":"Pfaff","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.humimm.2024.110814_b1160","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/s41419-018-1143-3","article-title":"IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment","volume":"9","author":"Mercurio","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.humimm.2024.110814_b1165","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/eji.202149706","article-title":"EGFR ligands synergistically increase IL-17A-induced expression of psoriasis signature genes in human keratinocytes via IkappaBzeta and Bcl3","volume":"52","author":"Dai","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1170","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/j.jid.2022.02.016","article-title":"IL-17A promotes psoriasis-associated keratinocyte proliferation through ACT1-dependent activation of YAP-AREG Axis","volume":"142","author":"Yu","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1175","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/stem.2656","article-title":"Brief report: interleukin-17A-dependent asymmetric stem cell divisions are increased in human psoriasis: a mechanism underlying benign hyperproliferation","volume":"35","author":"Charruyer","year":"2017","journal-title":"Stem Cells"},{"key":"10.1016\/j.humimm.2024.110814_b1180","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jdermsci.2020.09.002","article-title":"A novel role of IL-17A in contributing to the impaired suppressive function of Tregs in psoriasis","volume":"101","author":"Liu","year":"2021","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b1185","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/exd.13722","article-title":"The human IL-17A\/F heterodimer regulates psoriasis-associated genes through IkappaBzeta","volume":"27","author":"Bertelsen","year":"2018","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1190","first-page":"30","article-title":"Role of IL-17A and neutrophilic granulocytes in the pathogenesis of psoriasis","volume":"82","author":"Smolyannikova","year":"2020","journal-title":"Arkh. Patol."},{"key":"10.1016\/j.humimm.2024.110814_b1195","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/1346-8138.15507","article-title":"Pathogenic implication of epidermal scratch injury in psoriasis and atopic dermatitis","volume":"47","author":"Furue","year":"2020","journal-title":"J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1200","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/abbs\/gmz095","article-title":"FGF-7 facilitates the process of psoriasis by inducing TNF-alpha expression in HaCaT cells","volume":"51","author":"Pu","year":"2019","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"10.1016\/j.humimm.2024.110814_b1205","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.4049\/jimmunol.164.12.6621","article-title":"Up-regulation of macrophage inflammatory protein-3 alpha\/CCL20 and CC chemokine receptor 6 in psoriasis","volume":"164","author":"Homey","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1210","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1046\/j.1523-1747.2002.19624.x","article-title":"The chemokine receptor CCR6 identifies interferon-gamma expressing T cells and is decreased in atopic dermatitis as compared with psoriasis","volume":"119","author":"Ong","year":"2002","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1215","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1517\/14728222.2010.504716","article-title":"CCR6 as a possible therapeutic target in psoriasis","volume":"14","author":"Hedrick","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.humimm.2024.110814_b1220","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/j.jid.2020.12.034","article-title":"CCR4 involvement in the expansion of T helper type 17 cells in a mouse model of psoriasis","volume":"141","author":"Matsuo","year":"2021","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1225","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3390\/ijms21020434","article-title":"The EGFR-ERK\/JNK-CCL20 pathway in scratched keratinocytes may underpin koebnerization in psoriasis patients","volume":"21","author":"Furue","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b1230","first-page":"9567","article-title":"Implications of interleukin-17 in psoriatic lesions as Koebner phenomenon caused by recurrent occupational burns","volume":"15","author":"Sato","year":"2023","journal-title":"Dermatol. Rep."},{"key":"10.1016\/j.humimm.2024.110814_b1235","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/jid.2009.65","article-title":"Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis","volume":"129","author":"Harper","year":"2009","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1240","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1346-8138.2010.00935.x","article-title":"CD147 is highly expressed on peripheral blood neutrophils from patients with psoriasis and induces neutrophil chemotaxis","volume":"37","author":"Lu","year":"2010","journal-title":"J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1245","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.4049\/jimmunol.1800189","article-title":"miR-340 alleviates psoriasis in mice through direct targeting of IL-17A","volume":"201","author":"Bian","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1250","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1255","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.jid.2018.02.037","article-title":"IL-17C: a unique epithelial cytokine with potential for targeting across the spectrum of atopic dermatitis and psoriasis","volume":"138","author":"Guttman-Yassky","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1260","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jid.2019.01.006","article-title":"Imiquimod-induced psoriasis in mice depends on the IL-17 signaling of keratinocytes","volume":"139","author":"Moos","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1265","first-page":"317","article-title":"Serum levels of IL-10 and IL-22 cytokines in patients with psoriasis","volume":"13","author":"Sobhan","year":"2016","journal-title":"Iran. J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1270","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cellimm.2014.06.007","article-title":"An increased proportion of circulating Th22 and Tc22 cells in psoriasis","volume":"290","author":"Luan","year":"2014","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1275","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/1346-8138.12248","article-title":"Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis","volume":"40","author":"Shimauchi","year":"2013","journal-title":"J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1280","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10495-020-01623-3","article-title":"Elevated IL-22 in psoriasis plays an anti-apoptotic role in keratinocytes through mediating Bcl-xL\/Bax","volume":"25","author":"Wang","year":"2020","journal-title":"Apoptosis"},{"key":"10.1016\/j.humimm.2024.110814_b1285","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11596-007-0533-z","article-title":"The expression of interleukin-22 and S100A7, A8, A9 mRNA in patients with psoriasis vulgaris","volume":"27","author":"Liu","year":"2007","journal-title":"J. Huazhong Univ. Sci. Technolog. Med. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b1290","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2249.2007.03511.x","article-title":"A role for T cell-derived interleukin 22 in psoriatic skin inflammation","volume":"150","author":"Boniface","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1295","doi-asserted-by":"crossref","first-page":"705","DOI":"10.5114\/ada.2020.100481","article-title":"Interleukin 22 and 6 serum concentrations decrease under long-term biologic therapy in psoriasis","volume":"37","author":"Olejniczak-Staruch","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.humimm.2024.110814_b1300","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1038\/s41598-018-23510-3","article-title":"Regulation of IL-22BP in psoriasis","volume":"8","author":"Voglis","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.humimm.2024.110814_b1305","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.4049\/jimmunol.1700021","article-title":"Limited presence of IL-22 binding protein, a natural IL-22 inhibitor, strengthens psoriatic skin inflammation","volume":"198","author":"Martin","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1310","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jaci.2015.01.033","article-title":"Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis","volume":"136","author":"Mashiko","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1315","article-title":"Correlation of CD4+capital Te, cyrillic lymphocytes activation with interleukin IL-9, IL-17, IL- 22 profiles in the peripheral blood of patients with plaque psoriasis","volume":"75","author":"Mitskevich","year":"2021","journal-title":"Georgian Med. News"},{"key":"10.1016\/j.humimm.2024.110814_b1320","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jid.2019.08.444","article-title":"IL-36 promotes systemic IFN-I responses in severe forms of psoriasis","volume":"140","author":"Catapano","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1325","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1002\/eji.200939687","article-title":"The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis","volume":"39","author":"Wolk","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1330","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/jid.2011.468","article-title":"IFN-alpha enhances IL-22 receptor expression in keratinocytes: a possible role in the development of psoriasis","volume":"132","author":"Tohyama","year":"2012","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1335","first-page":"597","article-title":"IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation","volume":"118","author":"Ma","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.humimm.2024.110814_b1340","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4049\/jimmunol.1102224","article-title":"IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice","volume":"188","author":"Van Belle","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1345","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.4049\/jimmunol.178.4.2229","article-title":"The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis","volume":"178","author":"Sa","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1350","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.4049\/jimmunol.1001001","article-title":"IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A","volume":"186","author":"Rizzo","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1355","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/eji.200535503","article-title":"IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis","volume":"36","author":"Wolk","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1360","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jid.2018.07.032","article-title":"IL-22 down-regulates Cx43 expression and decreases gap junctional intercellular communication by activating the JNK pathway in psoriasis","volume":"139","author":"Liang","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1365","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/exd.13947","article-title":"Itching for an answer: a review of potential mechanisms of scalp itch in psoriasis","volume":"28","author":"Leon","year":"2019","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1370","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s10753-013-9715-y","article-title":"Targeting interleukin-22 in psoriasis","volume":"37","author":"Hao","year":"2014","journal-title":"Inflammation"},{"key":"10.1016\/j.humimm.2024.110814_b1375","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2147\/CCID.S257647","article-title":"IL-33\/13 axis and IL-4\/31 axis play distinct roles in inflammatory process and itch in psoriasis and atopic dermatitis","volume":"13","author":"Bodoor","year":"2020","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1380","article-title":"Interleukin 4 plasma levels in psoriasis vulgaris patients","volume":"10","author":"Zalewska","year":"2004","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.humimm.2024.110814_b1385","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1556\/AMicr.60.2013.2.7","article-title":"Expression patterns of Th1\/Th2 transcription factors in patients with guttate psoriasis","volume":"60","author":"Vanaki","year":"2013","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"10.1016\/j.humimm.2024.110814_b1390","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12291-011-0156-9","article-title":"Serum cytokine profile in psoriasis-a case-control study in a tertiary care hospital from northern India","volume":"26","author":"Verghese","year":"2011","journal-title":"Indian J. Clin. Biochem."},{"key":"10.1016\/j.humimm.2024.110814_b1395","first-page":"1493","article-title":"Increased expression of interleukin-4 receptors on psoriatic epidermal cells","volume":"148","author":"Prens","year":"1996","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.humimm.2024.110814_b1400","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.4049\/jimmunol.1401740","article-title":"IL-4 downregulates IL-1beta and IL-6 and Induces GATA3 in psoriatic epidermal cells: route of action of a Th2 cytokine","volume":"195","author":"Onderdijk","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1405","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000070942","article-title":"IL-4 expression by neutrophils in psoriasis lesional skin upon high-dose UVB exposure","volume":"207","author":"Piskin","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.humimm.2024.110814_b1410","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tips.2003.10.006","article-title":"Interleukin 4 treatment of psoriasis: are pleiotropic cytokines suitable therapies for autoimmune diseases?","volume":"24","author":"Martin","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b1415","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1517\/17460441.3.3.357","article-title":"Interleukin 4 as a potential drug candidate for psoriasis","volume":"3","author":"Weigert","year":"2008","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.humimm.2024.110814_b1420","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000235974","article-title":"Recombinant murine interleukin 4 protein therapy for psoriasis in a transgenic VEGF mouse model","volume":"219","author":"Ren","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.humimm.2024.110814_b1425","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/jgm.1459","article-title":"Gene therapy for psoriasis in the K14-VEGF transgenic mouse model by topical transdermal delivery of interleukin-4 using ultradeformable cationic liposome","volume":"12","author":"Li","year":"2010","journal-title":"J. Gene Med."},{"key":"10.1016\/j.humimm.2024.110814_b1430","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nm804","article-title":"Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease","volume":"9","author":"Ghoreschi","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.humimm.2024.110814_b1435","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/541709","article-title":"Assessment of lipocalin 2, clusterin, soluble tumor necrosis factor receptor-1, interleukin-6, homocysteine, and uric acid levels in patients with psoriasis","volume":"2014","author":"Ataseven","year":"2014","journal-title":"Dis. Markers"},{"key":"10.1016\/j.humimm.2024.110814_b1440","doi-asserted-by":"crossref","first-page":"121S","DOI":"10.1111\/1523-1747.ep12874991","article-title":"Interleukin-1 and interleukin-6 in psoriasis","volume":"95","author":"Prens","year":"1990","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1445","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1468-3083.2010.03647.x","article-title":"Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy","volume":"24","author":"Coimbra","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b1450","first-page":"500","article-title":"IL-6 and FAS (CD95) serum level in patients suffering from psoriasis and in relation to the lymphocyte subpopulations","volume":"59","author":"Pietrzak","year":"2004","journal-title":"Ann. Univ. Mariae Curie Sklodowska Med."},{"key":"10.1016\/j.humimm.2024.110814_b1455","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1523-1747.ep12477880","article-title":"Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis","volume":"97","author":"Neuner","year":"1991","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1460","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1073\/pnas.86.16.6367","article-title":"Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes","volume":"86","author":"Grossman","year":"1989","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b1465","first-page":"371","article-title":"Increased serum soluble Fas, tumor necrosis factor alpha and interleukin 6 concentrations in generalized pustular psoriasis","volume":"196","author":"Seishima","year":"1998","journal-title":"Dermatology"},{"key":"10.1016\/j.humimm.2024.110814_b1470","article-title":"Interleukin-6 as a marker of the activity of a pathological process in patients with psoriasis","volume":"80","author":"Koliadenko","year":"2005","journal-title":"Lik. Sprava"},{"key":"10.1016\/j.humimm.2024.110814_b1475","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cca.2012.05.007","article-title":"Serum interleukin-6 levels in response to methotrexate treatment in psoriatic patients","volume":"413","author":"Elango","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.humimm.2024.110814_b1480","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10517-022-05497-0","article-title":"IL-6 gene expression as a marker of pathological state in psoriasis and psoriatic arthritis","volume":"173","author":"Sobolev","year":"2022","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.humimm.2024.110814_b1485","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/14397595.2016.1174328","article-title":"Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis","volume":"27","author":"Muramatsu","year":"2017","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.humimm.2024.110814_b1490","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000246879","article-title":"Interleukin-6 and tumour necrosis factor levels decrease in the suction blister fluids of psoriatic patients during effective therapy","volume":"189","author":"Ameglio","year":"1994","journal-title":"Dermatology"},{"key":"10.1016\/j.humimm.2024.110814_b1495","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/BF02593914","article-title":"Serum interleukin-6 levels as an early marker of therapeutic response to UVB radiation and topical steroids in psoriatic patients","volume":"24","author":"Bonifati","year":"1994","journal-title":"Int. J. Clin. Lab. Res."},{"key":"10.1016\/j.humimm.2024.110814_b1500","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.4049\/jimmunol.0803721","article-title":"IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells","volume":"183","author":"Goodman","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1505","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00109-021-02073-3","article-title":"Soluble IL-6R-mediated IL-6 trans-signaling activation contributes to the pathological development of psoriasis","volume":"99","author":"Xu","year":"2021","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.humimm.2024.110814_b1510","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s004030050211","article-title":"Interleukin-11 production is increased in organ cultures of lesional skin of patients with active plaque-type psoriasis as compared with nonlesional and normal skin. Similarity to interleukin-1 beta, interleukin-6 and interleukin-8","volume":"289","author":"Ameglio","year":"1997","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b1515","first-page":"385","article-title":"Expression of interleukin-6-like molecules and tumour necrosis factor after topical treatment of psoriasis with a new vitamin D analogue (MC 903)","volume":"69","author":"Oxholm","year":"1989","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b1520","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2340\/0001555572165168","article-title":"Interleukin-6 in normal skin and psoriasis","volume":"72","author":"Castells-Rodellas","year":"1992","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b1525","first-page":"195","article-title":"Interleukin-6 in the epidermis of patients with psoriasis before and during PUVA treatment","volume":"69","author":"Oxholm","year":"1989","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b1530","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s004030050450","article-title":"Psoriatic fibroblasts secrete lower amounts of IL-6 than healthy fibroblasts before and after stimulation with TNF-alpha","volume":"291","author":"Fransson","year":"1999","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b1535","article-title":"IL-6R\/Signal transducer and activator of transcription 3 signaling in keratinocytes rather than in T cells induces psoriasis-like dermatitis in mice","author":"Ravipati","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1540","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0923-1811(99)00031-6","article-title":"Overexpression of monocyte-derived cytokines in active psoriasis: a relation to coexistent arthropathy","volume":"21","author":"Nishibu","year":"1999","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b1545","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0923-1811(96)00562-2","article-title":"Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments","volume":"14","author":"Mizutani","year":"1997","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b1550","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1006\/bbrc.2000.3806","article-title":"Insulin-like growth factor II induces interleukin-6 expression via NFkappaB activation in psoriasis","volume":"278","author":"Kwon","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.humimm.2024.110814_b1555","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00403-010-1033-8","article-title":"Involvement of IL-17F via the induction of IL-6 in psoriasis","volume":"302","author":"Fujishima","year":"2010","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b1560","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1002\/eji.1830220835","article-title":"Synergistic induction of interleukin-6 by tumor necrosis factor and lithium chloride in mice: possible role in the triggering and exacerbation of psoriasis by lithium treatment","volume":"22","author":"Beyaert","year":"1992","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1565","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151913","article-title":"IL-6 signaling in myelomonocytic cells is not crucial for the development of IMQ-induced psoriasis","volume":"11","author":"Klebow","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.humimm.2024.110814_b1570","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2249.2012.04618.x","article-title":"Experimentally induced psoriatic lesion associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing IL-33 and IL-6 receptor","volume":"169","author":"Suttle","year":"2012","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1575","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjd.19133","article-title":"Leptin induces interleukin-6 production in keratinocytes via decreased expression of caveolin-1: a possible link between obesity and psoriatic inflammation","volume":"183","author":"Watanabe","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1580","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/0019-5154.55631","article-title":"Cell proliferation and cytokine induction by TNF-alpha of psoriatic keratinocytes are not different from normal keratinocytes in vitro","volume":"54","author":"Takahashi","year":"2009","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1585","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/BF00372034","article-title":"Interleukin-6 in psoriasis: expression and mitogenicity studies","volume":"284","author":"Elder","year":"1992","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b1590","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF00371814","article-title":"In situ expression of messenger RNA of interleukin-1 and interleukin-6 in psoriasis: interleukin-6 involved in formation of psoriatic lesions","volume":"283","author":"Ohta","year":"1991","journal-title":"Arch. Dermatol.Res"},{"key":"10.1016\/j.humimm.2024.110814_b1595","doi-asserted-by":"crossref","first-page":"135S","DOI":"10.1111\/1523-1747.ep12876121","article-title":"Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis","volume":"94","author":"Krueger","year":"1990","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1600","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jid.2016.11.022","article-title":"IL-6 differs from TNF-alpha: unpredicted clinical effects caused by IL-6 blockade in psoriasis","volume":"137","author":"Blauvelt","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1605","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jid.2016.10.021","article-title":"Induction of alternative proinflammatory cytokines accounts for sustained psoriasiform skin inflammation in IL-17C+IL-6KO mice","volume":"137","author":"Fritz","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1610","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cyto.2014.01.008","article-title":"Polymorphisms in the TNF-alpha and IL-10 gene promoters and risk of psoriasis and correlation with disease severity","volume":"66","author":"Karam","year":"2014","journal-title":"Cytokine"},{"key":"10.1016\/j.humimm.2024.110814_b1615","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jdermsci.2004.10.002","article-title":"Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility","volume":"37","author":"Kingo","year":"2005","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b1620","first-page":"62","article-title":"Analysis of key markers: IL-10\/sHLA-G in psoriasis patients and the identification of 14-bp INDEL in the HLA-G gene","volume":"157","author":"Bieniek-Kobuszewska","year":"2022","journal-title":"Ital. J. Dermatol. Venerol."},{"key":"10.1016\/j.humimm.2024.110814_b1625","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00403-008-0886-6","article-title":"Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of psoriatic patients: preliminary study on a possible correlation between generalized immune status, treatments and disease","volume":"300","author":"Borghi","year":"2008","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b1630","first-page":"117","article-title":"IL-10 levels are decreased in psoriatic lesional skin as compared to the psoriatic lesion-free and normal skin suction blister fluids","volume":"8","author":"Mussi","year":"1994","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.humimm.2024.110814_b1635","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/clin.1994.1170","article-title":"Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques","volume":"73","author":"Nickoloff","year":"1994","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.humimm.2024.110814_b1640","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.4049\/jimmunol.159.12.6291","article-title":"Demonstration and functional analysis of IL-10 receptors in human epidermal cells: decreased expression in psoriatic skin, down-modulation by IL-8, and up-regulation by an antipsoriatic glucocorticosteroid in normal cultured keratinocytes","volume":"159","author":"Michel","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1645","first-page":"21","article-title":"A possible pathogenic role of CD4+CD25+ T-regulatory cells in psoriasis","volume":"14","author":"Shehata","year":"2007","journal-title":"Egypt. J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1650","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jdermsci.2015.11.003","article-title":"IL-10-producing regulatory B cells are decreased in patients with psoriasis","volume":"81","author":"Hayashi","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b1655","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clim.2017.04.010","article-title":"IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFNgamma-producing T cells","volume":"184","author":"Mavropoulos","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1660","article-title":"TLR2 deficiency exacerbates imiquimod-induced psoriasis-like skin inflammation through decrease in regulatory T cells and impaired IL-10 production","volume":"21","author":"Nakao","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b1665","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.15252\/emmm.201404114","article-title":"Specific roles for dendritic cell subsets during initiation and progression of psoriasis","volume":"6","author":"Glitzner","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.humimm.2024.110814_b1670","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/exd.13403","article-title":"Imiquimod-applied Interleukin-10 deficient mice better reflects severe and persistent psoriasis with systemic inflammatory state","volume":"27","author":"Jin","year":"2018","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1675","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.0022-202x.2001.01317.x","article-title":"Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings","volume":"116","author":"Asadullah","year":"2001","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1680","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1172\/JCI1476","article-title":"IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach","volume":"101","author":"Asadullah","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.humimm.2024.110814_b1685","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1046\/j.1523-1747.2002.01731.x","article-title":"Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis","volume":"118","author":"Friedrich","year":"2002","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1690","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1523-1747.2001.01248.x","article-title":"Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8\/CXCR2 pathway and normalization of keratinocyte maturation","volume":"116","author":"Reich","year":"2001","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1695","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/archderm.138.10.1341","article-title":"Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10","volume":"138","author":"Kimball","year":"2002","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1700","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.4049\/jimmunol.154.6.2668","article-title":"Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7\u20131 (CD80) and B7\u20132 (CD86) expression","volume":"154","author":"Mitra","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1705","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1046\/j.1523-1747.1998.00444.x","article-title":"Treatment of psoriasis with interleukin-10","volume":"111","author":"Reich","year":"1998","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1710","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1189\/jlb.0408249","article-title":"Comprehensive biomarker monitoring in cytokine therapy: heterogeneous, time-dependent, and persisting immune effects of interleukin-10 application in psoriasis","volume":"85","author":"Docke","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.humimm.2024.110814_b1715","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1172\/JCI6910","article-title":"Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions","volume":"104","author":"Trepicchio","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.humimm.2024.110814_b1720","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0923-1811(03)00148-8","article-title":"Up-regulation of interleukin-13 receptor alpha1 on human keratinocytes in the skin of psoriasis and atopic dermatitis","volume":"33","author":"Wongpiyabovorn","year":"2003","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b1725","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1046\/j.1523-1747.2002.19509.x","article-title":"Interleukin-13 receptor in psoriatic keratinocytes: overexpression of the mRNA and underexpression of the protein","volume":"119","author":"Cancino-Diaz","year":"2002","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1730","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-2133.2005.06665.x","article-title":"Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis","volume":"153","author":"Li","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1735","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1038\/jid.2014.308","article-title":"IL-19 is a component of the pathogenetic IL-23\/IL-17 cascade in psoriasis","volume":"134","author":"Witte","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1740","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1038\/s41598-019-41609-z","article-title":"Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay","volume":"9","author":"Konrad","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.humimm.2024.110814_b1745","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12864-015-1508-2","article-title":"Transcriptional landscape of psoriasis identifies the involvement of IL36 and IL36RN","volume":"16","author":"Keermann","year":"2015","journal-title":"BMC Genomics"},{"key":"10.1016\/j.humimm.2024.110814_b1750","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1365-2133.2005.06800.x","article-title":"The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis","volume":"153","author":"Otkjaer","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1755","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/j.1523-1747.2003.12626.x","article-title":"Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol","volume":"121","author":"Romer","year":"2003","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1760","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.clim.2005.06.012","article-title":"Detection of IL-20 and its receptors on psoriatic skin","volume":"117","author":"Wei","year":"2005","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b1765","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1196\/annals.1423.039","article-title":"Interleukin-20 as a target in psoriasis treatment","volume":"1110","author":"Stenderup","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b1770","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/exd.12371","article-title":"Interleukin 20 protein locates to distinct mononuclear cells in psoriatic skin","volume":"23","author":"Bech","year":"2014","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1775","first-page":"327","article-title":"Knockdown of interleukin 20 receptor 2 (IL-20R2) inhibits the development of psoriasis induced by imiquimod in mice","volume":"35","author":"Lin","year":"2019","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"10.1016\/j.humimm.2024.110814_b1780","first-page":"2777","article-title":"Interleukin-20\u2013a new target in psoriasis treatment","volume":"170","author":"Stenderup","year":"2008","journal-title":"Ugeskr. Laeger"},{"key":"10.1016\/j.humimm.2024.110814_b1785","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2133.2008.08890.x","article-title":"Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model","volume":"160","author":"Stenderup","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1790","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jid.2019.06.127","article-title":"IL-20-receptor signaling delimits IL-17 production in psoriatic inflammation","volume":"140","author":"Ha","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1795","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2013.10.009","article-title":"Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis-like skin inflammation in mice","volume":"39","author":"Kumari","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.humimm.2024.110814_b1800","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.immuni.2018.03.019","article-title":"An Interleukin-25-mediated autoregulatory circuit in keratinocytes plays a pivotal role in psoriatic skin inflammation","volume":"48","author":"Xu","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.humimm.2024.110814_b1805","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.jid.2016.06.009","article-title":"Keratinocyte-Derived IL-17E contributes to inflammation in psoriasis","volume":"136","author":"Senra","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1810","doi-asserted-by":"crossref","first-page":"657","DOI":"10.5114\/ada.2021.108926","article-title":"Significance of interleukin-31 (IL-31) gene polymorphisms and IL-31 serum level in psoriasis in correlation with pruritus","volume":"38","author":"Purzycka-Bohdan","year":"2021","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.humimm.2024.110814_b1815","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156531","article-title":"Increased tissue expression of IL-31 in patients with psoriasis","volume":"176","author":"Wongjirattikarn","year":"2024","journal-title":"Cytokine"},{"key":"10.1016\/j.humimm.2024.110814_b1820","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5021\/ad.2020.32.1.1","article-title":"Characteristics of pruritus according to morphological phenotype of psoriasis and association with neuropeptides and interleukin-31","volume":"32","author":"Park","year":"2020","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1825","doi-asserted-by":"crossref","first-page":"e05621","DOI":"10.1016\/j.heliyon.2020.e05621","article-title":"Increased serum IL-31 levels in chronic spontaneous urticaria and psoriasis with pruritic symptoms","volume":"6","author":"Chaowattanapanit","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.humimm.2024.110814_b1830","first-page":"289","article-title":"The interferon system in psoriasis","volume":"10","author":"Vignale","year":"1982","journal-title":"Med. Cutan. Ibero Lat. Am."},{"key":"10.1016\/j.humimm.2024.110814_b1835","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2133.1986.tb02800.x","article-title":"The effect of Goeckerman therapy on interferon in serum and suction blister fluid from patients with psoriasis","volume":"114","author":"Livden","year":"1986","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1840","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/1523-1747.ep12461005","article-title":"Decreased production of interferon in whole blood cultures derived from patients with psoriasis","volume":"90","author":"Kapp","year":"1988","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1845","first-page":"25","article-title":"Serum levels of interferons and TNF-alpha are not correlated to psoriasis activity and therapy","volume":"186","author":"Tigalonova","year":"1994","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"10.1016\/j.humimm.2024.110814_b1850","doi-asserted-by":"crossref","first-page":"e2737","DOI":"10.1371\/journal.pone.0002737","article-title":"Type I interferon: potential therapeutic target for psoriasis?","volume":"3","author":"Yao","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.humimm.2024.110814_b1855","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.0022-202X.2003.22113.x","article-title":"In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered","volume":"122","author":"van der Fits","year":"2004","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1860","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.intimp.2012.04.003","article-title":"Monocyte-derived interferon-alpha primed dendritic cells in the pathogenesis of psoriasis: new pieces in the puzzle","volume":"13","author":"Farkas","year":"2012","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.humimm.2024.110814_b1865","article-title":"Expression of the class II antigens of the major histocompatibility complex on the blood cells of psoriasis patients and its alteration under the influence of interferon preparations","volume":"10","author":"Medunitsyn","year":"1989","journal-title":"Vestn Dermatol. Venerol."},{"key":"10.1016\/j.humimm.2024.110814_b1870","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/exd.14513","article-title":"Small plaque psoriasis re-visited: A type of psoriasis mediated by a type-I interferon pathway","volume":"31","author":"Khosravi-Hafshejani","year":"2022","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1875","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.humimm.2024.110814_b1880","doi-asserted-by":"crossref","first-page":"e000239","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-alpha blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.humimm.2024.110814_b1885","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.humimm.2024.110814_b1890","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jdermsci.2009.08.006","article-title":"Psoriasis patients generate increased serum levels of autoantibodies to tumor necrosis factor-alpha and interferon-alpha","volume":"56","author":"Bergman","year":"2009","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b1895","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2133.1991.tb14774.x","article-title":"Psoriasis induced by interferon-alpha","volume":"125","author":"Funk","year":"1991","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1900","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/archderm.1991.01680050156027","article-title":"Psoriasis with articular involvement induced by interferon alfa","volume":"127","author":"Jucgla","year":"1991","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1905","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/S0140-6736(86)91502-3","article-title":"Psoriasis and alpha-interferon","volume":"1","author":"Quesada","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.humimm.2024.110814_b1910","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s001050050388","article-title":"Interferon-alpha-induced psoriasis vulgaris","volume":"47","author":"Wolfer","year":"1996","journal-title":"Hautarzt"},{"key":"10.1016\/j.humimm.2024.110814_b1915","first-page":"519","article-title":"Psoriasis induced by interferon-alpha. Apropos of a case","volume":"147","author":"Nguyen","year":"1996","journal-title":"Ann. Med. Interne (Paris)"},{"key":"10.1016\/j.humimm.2024.110814_b1920","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1111\/pde.13418","article-title":"Interferon-alpha induced psoriasis in a teenager","volume":"35","author":"Mendieta","year":"2018","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1925","doi-asserted-by":"crossref","first-page":"e15834","DOI":"10.1111\/dth.15834","article-title":"Guttate psoriasis induced by interferon alfa-2b suppository treatment for high-grade cervical intraepithelial neoplasia","volume":"35","author":"Li","year":"2022","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.humimm.2024.110814_b1930","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1159\/000520533","article-title":"Newly developed psoriasis in a patient with telangiectasia macularis eruptiva perstans and systemic mastocytosis treated with interferon","volume":"13","author":"Pecova","year":"2021","journal-title":"Case Rep. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1935","doi-asserted-by":"crossref","first-page":"479","DOI":"10.5021\/ad.2013.25.4.479","article-title":"Extensive psoriasis induced by pegylated interferon alfa-2a and ribavirin in the treatment of chronic hepatitis C","volume":"25","author":"Kim","year":"2013","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1940","first-page":"760","article-title":"New-onset psoriasis following treatment with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C","volume":"11","author":"Horev","year":"2009","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.humimm.2024.110814_b1945","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1157\/13109548","article-title":"Pegylated interferon alfa-induced psoriasis","volume":"129","author":"Gonzalez-Lopez","year":"2007","journal-title":"Med. Clin. (Barc.)"},{"key":"10.1016\/j.humimm.2024.110814_b1950","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1752-1947-1-86","article-title":"Extensive psoriasis induced by pegylated interferon: a case report","volume":"1","author":"Citro","year":"2007","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.humimm.2024.110814_b1955","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.0736-8046.2004.21512.x","article-title":"Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection","volume":"21","author":"Seckin","year":"2004","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b1960","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/pmj.76.896.365","article-title":"Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C","volume":"76","author":"Taylor","year":"2000","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.humimm.2024.110814_b1965","first-page":"324","article-title":"The treatment of hepatitis B and C with interferon-alpha can induce or aggravate psoriasis","volume":"19","author":"Cervoni","year":"1995","journal-title":"Gastroenterol. Clin. Biol."},{"key":"10.1016\/j.humimm.2024.110814_b1970","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000247916","article-title":"Exacerbation of psoriasis after treatment with alpha-interferon","volume":"181","author":"Kusec","year":"1990","journal-title":"Dermatologica"},{"key":"10.1016\/j.humimm.2024.110814_b1975","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1055\/s-2008-1066559","article-title":"Exacerbation of psoriasis during alpha-interferon therapy","volume":"114","author":"Hartmann","year":"1989","journal-title":"Dtsch. Med. Wochenschr."},{"key":"10.1016\/j.humimm.2024.110814_b1980","first-page":"800","article-title":"Exacerbation of psoriasis by treatment with alpha interferon","volume":"103","author":"Revenga Arranz","year":"1994","journal-title":"Med. Clin. (Barc.)"},{"key":"10.1016\/j.humimm.2024.110814_b1985","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2340\/0001555573395","article-title":"Psoriasis exacerbation induced by interferon-alpha. Report of two cases","volume":"73","author":"Pauluzzi","year":"1993","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b1990","first-page":"309","article-title":"Psoriasis exacerbated by alpha-interferon therapy in a case of chronic myelogenous leukemia","volume":"35","author":"Matsuoka","year":"1994","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.humimm.2024.110814_b1995","first-page":"1756","article-title":"Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis","volume":"88","author":"Georgetson","year":"1993","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.humimm.2024.110814_b2000","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2230.2000.00655-4.x","article-title":"Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C","volume":"25","author":"Downs","year":"2000","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2005","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1111\/j.1440-0960.2011.00767.x","article-title":"Generalized flare of pustular psoriasis induced by PEGylated interferon-alpha2b therapy for chronic hepatitis C","volume":"53","author":"Wu","year":"2012","journal-title":"Australas. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/15569527.2015.1020545","article-title":"Exacerbation of psoriasis induced by interferon-alpha treatment for melanoma","volume":"35","author":"Tas","year":"2016","journal-title":"Cutan. Ocul. Toxicol."},{"key":"10.1016\/j.humimm.2024.110814_b2015","first-page":"48","article-title":"Exacerbation of Skin Lesions in a 50 year old Man with Psoriasis during Treatment by Pegylated Interferon","volume":"4","author":"Sharifi","year":"2012","journal-title":"Middle East J Dig Dis"},{"key":"10.1016\/j.humimm.2024.110814_b2020","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/MEG.0b013e32816e070b","article-title":"Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C","volume":"19","author":"Yurci","year":"2007","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.humimm.2024.110814_b2025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00044011-200424070-00006","article-title":"Verrucous psoriasis in a patient with chronic C hepatitis treated with interferon","volume":"24","author":"Scavo","year":"2004","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.humimm.2024.110814_b2030","first-page":"221","article-title":"Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia","volume":"4","author":"Ladoyanni","year":"2005","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2035","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ajh.10405","article-title":"Major depression and psoriasis activation due to interferon-alpha in a patient with chronic myeloid leukemia; \u201coverlooked and\/or misdiagnosed adverse reaction in malignant disease\u201d","volume":"74","author":"Besisik","year":"2003","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.humimm.2024.110814_b2040","first-page":"423","article-title":"The exacerbation of psoriasis during treatment with alfa interferon","volume":"88","author":"Pellicano","year":"1997","journal-title":"Recenti Prog. Med."},{"key":"10.1016\/j.humimm.2024.110814_b2045","first-page":"124","article-title":"Psoriasis occurring predominantly on warts. Possible involvement of interferon alfa","author":"Shiohara","year":"1816","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2050","first-page":"1771","article-title":"Arthritis in a patient with psoriasis after interferon-alpha therapy for chronic hepatitis C","volume":"21","author":"Makino","year":"1994","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.humimm.2024.110814_b2055","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(86)92161-6","article-title":"Effect of interferon on psoriasis","volume":"2","author":"Harrison","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.humimm.2024.110814_b2060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000248777","article-title":"Parenteral interferon-alpha treatment of psoriasis","volume":"175","author":"Neumann","year":"1987","journal-title":"Dermatologica"},{"key":"10.1016\/j.humimm.2024.110814_b2065","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0190-9622(99)70373-7","article-title":"Remission of psoriasis after treatment with interferon-alfa and 2-chlordeoxyadenosine for hairy cell leukemia","volume":"41","author":"Ilyas","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2070","doi-asserted-by":"crossref","first-page":"S411","DOI":"10.5021\/ad.2011.23.S3.S411","article-title":"Psoriasis and hepatitis C: improvement with interferon","volume":"23","author":"Habte-Gabr","year":"2011","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2075","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000247266","article-title":"Interferon-induced psoriasis in a patient with chronic hepatitis C","volume":"187","author":"Garcia-Lora","year":"1993","journal-title":"Dermatology"},{"key":"10.1016\/j.humimm.2024.110814_b2080","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1684\/ejd.2015.2602","article-title":"Onset of psoriasis upon interferon beta treatment in a multiple sclerosis patient","volume":"26","author":"Amschler","year":"2016","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2085","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1365-2133.2008.09005.x","article-title":"New-onset psoriasis in a patient treated with interferon beta-1a","volume":"160","author":"Lopez-Lerma","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2090","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/archderm.1990.01670350131024","article-title":"Psoriasis induced at the injection site of recombinant interferons","volume":"126","author":"Kowalzick","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.humimm.2024.110814_b2095","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0190-9622(97)80248-4","article-title":"Psoriasis flare caused by recombinant interferon beta injections","volume":"36","author":"Kowalzick","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.humimm.2024.110814_b2100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10072-009-0184-x","article-title":"Psoriasis during interferon beta treatment for multiple sclerosis","volume":"31","author":"La Mantia","year":"2010","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2105","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1212\/WNL.0000000000004501","article-title":"Teaching NeuroImages: Interferon-induced psoriasis flare in a multiple sclerosis case remits with dimethyl fumarate","volume":"89","author":"Tsivgoulis","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.humimm.2024.110814_b2110","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000018447","article-title":"Psoriasis associated with HCV and exacerbated by interferon alpha: complete clearance with acitretin during interferon alpha treatment for chronic active hepatitis","volume":"201","author":"Erkek","year":"2000","journal-title":"Dermatology"},{"key":"10.1016\/j.humimm.2024.110814_b2115","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0190-9622(07)80010-7","article-title":"Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis","volume":"34","author":"Webster","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/jir.2006.26.133","article-title":"Analysis of IFN-kappa expression in pathologic skin conditions: downregulation in psoriasis and atopic dermatitis","volume":"26","author":"Scarponi","year":"2006","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.humimm.2024.110814_b2125","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2147\/CCID.S218243","article-title":"Interferon kappa is up-regulated in psoriasis and it up-regulates psoriasis-associated cytokines in vivo","volume":"12","author":"Li","year":"2019","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2130","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jdermsci.2016.02.003","article-title":"Up-regulation of receptor antagonist interleukin-1 family members in psoriasis and their regulation by pro-inflammatory cytokines","volume":"82","author":"Kim","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2135","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/sji.12117","article-title":"Association of disease severity with IL-1 levels in methotrexate-treated psoriasis patients","volume":"78","author":"Tamilselvi","year":"2013","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2140","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jid.2020.07.012","article-title":"Enhanced inflammasome activity in patients with psoriasis promotes systemic inflammation","volume":"141","author":"Verma","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2145","first-page":"133","article-title":"IL-1 alpha, IL-1 beta and psoriasis: conflicting results in the literature. Opposite behaviour of the two cytokines in lesional or non-lesional extracts of whole skin","volume":"11","author":"Bonifati","year":"1997","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.humimm.2024.110814_b2150","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cyto.2005.12.001","article-title":"Interleukin-1: a key inflammatory mediator in psoriasis?","volume":"33","author":"Mee","year":"2006","journal-title":"Cytokine"},{"key":"10.1016\/j.humimm.2024.110814_b2155","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/archderm.1991.01680050071006","article-title":"Interleukin 1 alpha, tumor necrosis factor alpha, and interferon gamma in psoriasis","volume":"127","author":"Gomi","year":"1991","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2160","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.4049\/jimmunol.144.12.4593","article-title":"IL-1 activity is reduced in psoriatic skin. Decreased IL-1 alpha and increased nonfunctional IL-1 beta","volume":"144","author":"Cooper","year":"1990","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2165","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1620\/tjem.161.159","article-title":"Decreased levels of IL-1 alpha and beta in psoriatic lesional skin","volume":"161","author":"Takematsu","year":"1990","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.humimm.2024.110814_b2170","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/10520295.2021.1954692","article-title":"Investigation of the role of IL18, IL-1beta and NLRP3 inflammasome in reducing expression of FLG-2 protein in Psoriasis vulgaris skin lesions","volume":"97","author":"Akhlaghi","year":"2022","journal-title":"Biotech. Histochem."},{"key":"10.1016\/j.humimm.2024.110814_b2175","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jid.2018.07.025","article-title":"A Critical Role of the IL-1beta-IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis","volume":"139","author":"Cai","year":"2019","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2180","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/BF00371833","article-title":"In situ hybridization analysis of cytokine, proto-oncogene and tumour suppressor gene expression in psoriasis","volume":"285","author":"Schmid","year":"1993","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b2185","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-2249.2001.01421.x","article-title":"Pathogenic function of IL-1 beta in psoriasiform skin lesions of flaky skin (fsn\/fsn) mice","volume":"123","author":"Schon","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2190","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/eji.1830250623","article-title":"Enhanced production of biologically active interleukin-1 alpha and interleukin-1 beta by psoriatic epidermal cells ex vivo: evidence of increased cytosolic interleukin-1 beta levels and facilitated interleukin-1 release","volume":"25","author":"Debets","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2195","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/0300060515598902","article-title":"Salivary interleukin-1beta: Oral inflammatory biomarker in patients with psoriasis","volume":"44","author":"Ganzetti","year":"2016","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.humimm.2024.110814_b2200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.571319","article-title":"Psoriasis Is Associated With Elevated Gut IL-1alpha and Intestinal Microbiome Alterations","volume":"11","author":"Yegorov","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2205","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.4049\/jimmunol.1003162","article-title":"IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression","volume":"186","author":"Johnston","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2210","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI115896","article-title":"Interleukin-1 receptor antagonist in normal and psoriatic epidermis","volume":"90","author":"Hammerberg","year":"1992","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.humimm.2024.110814_b2215","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13578-024-01238-0","article-title":"Impaired autophagy in myeloid cells aggravates psoriasis-like skin inflammation through the IL-1beta\/CXCL2\/neutrophil axis","volume":"14","author":"Lee","year":"2024","journal-title":"Cell Biosci."},{"key":"10.1016\/j.humimm.2024.110814_b2220","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2133.2011.10302.x","article-title":"Expression of interleukin (IL)-1 family members upon stimulation with IL-17 differs in keratinocytes derived from patients with psoriasis and healthy donors","volume":"165","author":"Muhr","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2225","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/ncomms2566","article-title":"Aldara activates TLR7-independent immune defence","volume":"4","author":"Walter","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.humimm.2024.110814_b2230","doi-asserted-by":"crossref","first-page":"7909","DOI":"10.12659\/MSM.911347","article-title":"Expression of NLPR3 in psoriasis is associated with enhancement of Interleukin-1beta and Caspase-1","volume":"24","author":"Su","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.humimm.2024.110814_b2235","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jid.2017.09.005","article-title":"CD100-Plexin-B2 promotes the inflammation in psoriasis by activating NF-kappaB and the inflammasome in keratinocytes","volume":"138","author":"Zhang","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2240","article-title":"FOSL1 regulates hyperproliferation and NLRP3-mediated inflammation of psoriatic keratinocytes through the NF-kB signaling via transcriptionally activating TRAF3","volume":"1871","author":"Liang","year":"2024","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.humimm.2024.110814_b2245","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/jid.2013.57","article-title":"A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis","volume":"133","author":"Jiang","year":"2013","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2250","doi-asserted-by":"crossref","first-page":"e0175153","DOI":"10.1371\/journal.pone.0175153","article-title":"Th17 micro-milieu regulates NLRP1-dependent caspase-5 activity in skin autoinflammation","volume":"12","author":"Zwicker","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.humimm.2024.110814_b2255","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/jid.2010.370","article-title":"Caspase-5 expression is upregulated in lesional psoriatic skin","volume":"131","author":"Salskov-Iversen","year":"2011","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2260","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/exd.12037","article-title":"Strong induction of AIM2 expression in human epidermis in acute and chronic inflammatory skin conditions","volume":"21","author":"de Koning","year":"2012","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2265","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002001","article-title":"Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions","volume":"3","author":"Dombrowski","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.humimm.2024.110814_b2270","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1600-0625.2011.01382.x","article-title":"Human keratinocytes express AIM2 and respond to dsDNA with IL-1beta secretion","volume":"20","author":"Kopfnagel","year":"2011","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2275","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000249347","article-title":"Interleukin-1-like activity in horny layer extracts: decreased activity in scale extracts of psoriasis and sterile pustular dermatoses","volume":"172","author":"Takematsu","year":"1986","journal-title":"Dermatologica"},{"key":"10.1016\/j.humimm.2024.110814_b2280","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2353\/ajpath.2007.061067","article-title":"The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis","volume":"171","author":"Mee","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.humimm.2024.110814_b2285","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/jid.2012.123","article-title":"Interleukin-1beta interferes with epidermal homeostasis through induction of insulin resistance: implications for psoriasis pathogenesis","volume":"132","author":"Buerger","year":"2012","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2290","doi-asserted-by":"crossref","first-page":"e0169788","DOI":"10.1371\/journal.pone.0169788","article-title":"Human S100A7 Induces Mature Interleukin1alpha Expression by RAGE-p38 MAPK-Calpain1 Pathway in Psoriasis","volume":"12","author":"Lei","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.humimm.2024.110814_b2295","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/jid.2012.512","article-title":"IL-1R1 signaling facilitates Munro's microabscess formation in psoriasiform imiquimod-induced skin inflammation","volume":"133","author":"Uribe-Herranz","year":"2013","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2300","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.4049\/jimmunol.1001227","article-title":"TNF, but not IL-6 and IL-17, is crucial for the development of T cell-independent psoriasis-like dermatitis in Il1rn-\/- mice","volume":"185","author":"Nakajima","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2305","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.0022-202X.2004.22305.x","article-title":"Psoriasis-like cutaneous inflammation in mice lacking interleukin-1 receptor antagonist","volume":"122","author":"Shepherd","year":"2004","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2310","first-page":"1902817","article-title":"Deficiency of Interleukin-1 receptor antagonist: a case with late onset severe inflammatory arthritis, nail psoriasis with onychomycosis and well responsive to adalimumab therapy","volume":"2019","author":"Kutukculer","year":"2019","journal-title":"Case Rep. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2315","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1468-3083.2003.00647.x","article-title":"Serum levels of interleukin-18 and s-ICAM-1 in patients affected by psoriasis: preliminary considerations","volume":"17","author":"Gangemi","year":"2003","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b2320","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3389\/fphar.2020.01238","article-title":"The inflammasome signaling proteins ASC and IL-18 as biomarkers of psoriasis","volume":"11","author":"Forouzandeh","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.humimm.2024.110814_b2325","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s004030100240","article-title":"Expression of IL-18 in psoriasis","volume":"293","author":"Ohta","year":"2001","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b2330","doi-asserted-by":"crossref","first-page":"61254","DOI":"10.1155\/2007\/61254","article-title":"Plasma interleukin-18 and dendritic cells in males with psoriasis vulgaris","volume":"2007","author":"Pietrzak","year":"2007","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.humimm.2024.110814_b2335","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13547500600565735","article-title":"Plasma and scales levels of interleukin 18 in comparison with other possible clinical and laboratory biomarkers of psoriasis activity","volume":"11","author":"Flisiak","year":"2006","journal-title":"Biomarkers"},{"key":"10.1016\/j.humimm.2024.110814_b2340","first-page":"210","article-title":"Elevated interleukin-18 protein expression in early active and progressive plaque-type psoriatic lesions","volume":"15","author":"Companjen","year":"2004","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.humimm.2024.110814_b2345","article-title":"Identification of IL-18 and soluble cell adhesion molecules in the gingival crevicular fluid as novel biomarkers of psoriasis","volume":"11","author":"Valenzuela","year":"2021","journal-title":"Life (Basel)"},{"key":"10.1016\/j.humimm.2024.110814_b2350","doi-asserted-by":"crossref","first-page":"713","DOI":"10.5114\/aoms.2011.24144","article-title":"Interleukin-18 expression and the response to treatment in patients with psoriasis","volume":"7","author":"Rasmy","year":"2011","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2355","doi-asserted-by":"crossref","first-page":"964","DOI":"10.5114\/aoms.2010.19309","article-title":"Interleukin-18 expression and the response to treatment in patients with psoriasis","volume":"6","author":"Mohamed Attia","year":"2010","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2360","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/13547500802033300","article-title":"Plasma TGF-beta1, TIMP-1, MMP-1 and IL-18 as a combined biomarker of psoriasis activity","volume":"13","author":"Flisiak","year":"2008","journal-title":"Biomarkers"},{"key":"10.1016\/j.humimm.2024.110814_b2365","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/00015550310016508","article-title":"Interleukin-18 levels in the plasma of psoriatic patients correlate with the extent of skin lesions and the PASI score","volume":"83","author":"Pietrzak","year":"2003","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b2370","first-page":"1394","article-title":"Expression of NLRP3 inflammasome in BALB\/c mice with imiquimod-induced psoriasis-like inflammation and therapeutic effect of mustard seed (Sinapis Alba Linn)","volume":"33","author":"Hu","year":"2013","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"10.1016\/j.humimm.2024.110814_b2375","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1007\/s00018-013-1425-y","article-title":"IL-18 in inflammatory and autoimmune disease","volume":"70","author":"Sedimbi","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2380","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/path.4848","article-title":"Proinflammatory effect of high-mobility group protein B1 on keratinocytes: an autocrine mechanism underlying psoriasis development","volume":"241","author":"Zhang","year":"2017","journal-title":"J. Pathol."},{"key":"10.1016\/j.humimm.2024.110814_b2385","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/CM9.0000000000000140","article-title":"Interleukin-18 exacerbates skin inflammation and affects microabscesses and scale formation in a mouse model of imiquimod-induced psoriasis","volume":"132","author":"Niu","year":"2019","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.humimm.2024.110814_b2390","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00403-017-1735-2","article-title":"Interleukin (IL)-18, cooperatively with IL-23, induces prominent inflammation and enhances psoriasis-like epidermal hyperplasia","volume":"309","author":"Shimoura","year":"2017","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b2395","first-page":"179","article-title":"Evaluating serum levels of IL-33, IL-36, IL-37 and gene expression of IL-37 in patients with psoriasis vulgaris","volume":"17","author":"Sehat","year":"2018","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2400","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/ced.12670","article-title":"Serum IL-33 levels are increased in patients with psoriasis","volume":"41","author":"Mitsui","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2405","doi-asserted-by":"crossref","first-page":"8465083","DOI":"10.1155\/2020\/8465083","article-title":"Alarmins HMGB1, IL-33, S100A7, and S100A12 in Psoriasis Vulgaris","volume":"2020","author":"Borsky","year":"2020","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.humimm.2024.110814_b2410","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/imm.13203","article-title":"Interleukin-33 alleviates psoriatic inflammation by suppressing the T helper type 17 immune response","volume":"160","author":"Chen","year":"2020","journal-title":"Immunology"},{"key":"10.1016\/j.humimm.2024.110814_b2415","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cyto.2019.02.019","article-title":"IL-33 contributes to disease severity in Psoriasis-like models of mouse","volume":"119","author":"Duan","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.humimm.2024.110814_b2420","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7158014","article-title":"Possible roles of IL-33 in the innate-adaptive immune crosstalk of psoriasis pathogenesis","volume":"2019","author":"Cannavo","year":"2019","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.humimm.2024.110814_b2425","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3892\/etm.2015.2688","article-title":"Effect of TNF-alpha inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and -9 in psoriatic plaques","volume":"10","author":"Vageli","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.humimm.2024.110814_b2430","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00403-014-1447-9","article-title":"IL-33 is regulated by TNF-alpha in normal and psoriatic skin","volume":"306","author":"Balato","year":"2014","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b2435","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jid.2020.07.027","article-title":"An autocrine circuit of IL-33 in keratinocytes is involved in the progression of psoriasis","volume":"141","author":"Zeng","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2440","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13075-016-1042-x","article-title":"Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33","volume":"18","author":"Athari","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.humimm.2024.110814_b2445","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12964-023-01075-7","article-title":"IL-33-mediated activation of mast cells is involved in the progression of imiquimod-induced psoriasis-like dermatitis","volume":"21","author":"Zhou","year":"2023","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.humimm.2024.110814_b2450","first-page":"46","article-title":"Psoriasis-Specific RNA isoforms identified by RNA-Seq analysis of 173,446 transcripts","volume":"3","author":"Koks","year":"2016","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.humimm.2024.110814_b2455","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.jid.2016.03.020","article-title":"IL-36gamma is involved in psoriasis and allergic contact dermatitis","volume":"136","author":"Balato","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2460","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/09546634.2019.1689226","article-title":"Correlation analysis between IL-35, IL-36gamma, CCL27 and psoriasis vulgaris","volume":"32","author":"Chen","year":"2021","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.humimm.2024.110814_b2465","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/cup.14105","article-title":"IL-36alpha and IL-36gamma expressions in the differential diagnosis of palmoplantar psoriasis and palmoplantar eczema: A retrospective histopathologic and immunohistochemical study","volume":"49","author":"Erdem","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.humimm.2024.110814_b2470","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s11596-013-1164-1","article-title":"IL-36 cytokine expression and its relationship with p38 MAPK and NF-kappaB pathways in psoriasis vulgaris skin lesions","volume":"33","author":"He","year":"2013","journal-title":"J. Huazhong Univ. Sci. Technolog. Med. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2475","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cei.12761","article-title":"Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease","volume":"184","author":"Boutet","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2480","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jdermsci.2015.08.002","article-title":"Expression of IL-36 family cytokines and IL-37 but not IL-38 is altered in psoriatic skin","volume":"80","author":"Keermann","year":"2015","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2485","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis","volume":"131","author":"Carrier","year":"2011","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2490","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/cup.14115","article-title":"Interleukin 36 expression in psoriasis variants and other dermatologic diseases with psoriasis-like histopathologic features","volume":"49","author":"Aquino","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.humimm.2024.110814_b2495","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1016\/j.jid.2016.07.008","article-title":"IL-17 responses are the dominant inflammatory signal linking inverse, erythrodermic, and chronic plaque psoriasis","volume":"136","author":"Xing","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2500","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2340\/00015555-2265","article-title":"Interleukin-36gamma (IL-1F9) identifies psoriasis among patients with erythroderma","volume":"96","author":"Braegelmann","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b2505","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4103\/ijdvl.IJDVL_640_18","article-title":"Expression and correlation of interleukin-36gamma, claudin-1 and claudin-7 in psoriasis","volume":"85","author":"Pan","year":"2019","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"10.1016\/j.humimm.2024.110814_b2510","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jaci.2018.04.031","article-title":"Detection of IL-36gamma through noninvasive tape stripping reliably discriminates psoriasis from atopic eczema","volume":"142","author":"Berekmeri","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2515","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/jid.2014.532","article-title":"IL-36gamma (IL-1F9) is a biomarker for psoriasis skin lesions","volume":"135","author":"D'Erme","year":"2015","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2520","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1080\/09546634.2021.1967265","article-title":"Downregulation of interleukin 36gamma and its cleaver cathepsin G following treatment with narrow-band ultraviolet B phototherapy in psoriasis vulgaris","volume":"33","author":"El-Kalioby","year":"2022","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.humimm.2024.110814_b2525","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1038\/jid.2015.289","article-title":"Unprocessed Interleukin-36alpha regulates psoriasis-like skin inflammation in cooperation with Interleukin-1","volume":"135","author":"Milora","year":"2015","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2530","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2147\/DDDT.S194765","article-title":"Cathepsin G cleaves and activates IL-36gamma and promotes the inflammation of psoriasis","volume":"13","author":"Guo","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.humimm.2024.110814_b2535","doi-asserted-by":"crossref","first-page":"E2748","DOI":"10.1073\/pnas.1620954114","article-title":"Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36gamma","volume":"114","author":"Ainscough","year":"2017","journal-title":"PNAS"},{"key":"10.1016\/j.humimm.2024.110814_b2540","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jdermsci.2012.07.010","article-title":"Interleukin-36 cytokines enhance the production of host defense peptides psoriasin and LL-37 by human keratinocytes through activation of MAPKs and NF-kappaB","volume":"68","author":"Nguyen","year":"2012","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2545","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4049\/jimmunol.1701157","article-title":"IL-36alpha from Skin-Resident Cells Plays an Important Role in the Pathogenesis of Imiquimod-Induced Psoriasiform Dermatitis by Forming a Local Autoamplification Loop","volume":"201","author":"Hashiguchi","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2550","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.7150\/ijms.20809","article-title":"IL-36gamma inhibits differentiation and induces inflammation of keratinocyte via Wnt signaling pathway in psoriasis","volume":"14","author":"Wang","year":"2017","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2555","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fimmu.2018.00200","article-title":"IL-36gamma Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis","volume":"9","author":"Bridgewood","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2560","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jid.2023.09.267","article-title":"Mature IL-36gamma induces stratum corneum exfoliation in generalized pustular psoriasis by suppressing corneodesmosin","volume":"144","author":"Sato","year":"2024","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2565","first-page":"3","article-title":"Lemeille S et al.: IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis","author":"Goldstein","year":"2020","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.humimm.2024.110814_b2570","doi-asserted-by":"crossref","first-page":"20149","DOI":"10.1038\/s41598-020-76864-y","article-title":"Neutrophil extracellular traps are induced in a psoriasis model of interleukin-36 receptor antagonist-deficient mice","volume":"10","author":"Watanabe","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.humimm.2024.110814_b2575","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jid.2017.12.024","article-title":"Unopposed IL-36 Activity Promotes Clonal CD4(+) T-Cell Responses with IL-17A Production in Generalized Pustular Psoriasis","volume":"138","author":"Arakawa","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2580","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1172\/JCI63451","article-title":"Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk","volume":"122","author":"Tortola","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.humimm.2024.110814_b2585","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201900586","article-title":"Keratinocyte interleukin-36 receptor expression orchestrates psoriasiform inflammation in mice","volume":"3","author":"Hernandez-Santana","year":"2020","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.humimm.2024.110814_b2590","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jid.2018.12.003","article-title":"IL-36 signaling is essential for psoriatic inflammation through the augmentation of innate immune responses","volume":"139","author":"Ohko","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2595","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1111\/1346-8138.16023","article-title":"Generalized pustular psoriasis with deficiency of interleukin-36 receptor antagonist associated with sensorineural hearing impairment","volume":"48","author":"Ichiyama","year":"2021","journal-title":"J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2600","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000380876","article-title":"A case of old age-onset generalized pustular psoriasis with a deficiency of IL-36RN (DITRA) treated by granulocyte and monocyte apheresis","volume":"7","author":"Tominaga","year":"2015","journal-title":"Case Rep. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2605","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/jid.2013.285","article-title":"Loss of IL36RN function does not confer susceptibility to psoriasis vulgaris","volume":"134","author":"Berki","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2610","first-page":"9","article-title":"An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target","author":"Mahil","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.humimm.2024.110814_b2615","article-title":"Severe flare of generalized pustular psoriasis treated with spesolimab, an IL-36-directed monoclonal antibody","author":"Mateeva","year":"2024","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/j.humimm.2024.110814_b2620","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4049\/immunohorizons.2000083","article-title":"IL-37 expression is downregulated in lesional psoriasis skin","volume":"4","author":"Ronholt","year":"2020","journal-title":"Immunohorizons"},{"key":"10.1016\/j.humimm.2024.110814_b2625","doi-asserted-by":"crossref","first-page":"e12943","DOI":"10.1111\/dth.12943","article-title":"Activation of mast cells mediates inflammatory response in psoriasis: Potential new therapeutic approach with IL-37","volume":"32","author":"Conti","year":"2019","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.humimm.2024.110814_b2630","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.4049\/jimmunol.1300047","article-title":"IL-37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production","volume":"192","author":"Teng","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2635","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/clin.1996.4313","article-title":"Increased interleukin-7 concentrations in lesional skin and in the sera of patients with plaque-type psoriasis","volume":"83","author":"Bonifati","year":"1997","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.humimm.2024.110814_b2640","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1111\/ajd.12965","article-title":"Expression of B and T lymphocyte attenuator, retinoid-related orphan receptor gamma-isoform-t and interleukin 7 in psoriasis vulgaris","volume":"60","author":"Youssef","year":"2019","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.humimm.2024.110814_b2645","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/000155599750011606","article-title":"Interleukin-8 plays its role at local level in psoriasis vulgaris","volume":"79","author":"Sticherling","year":"1999","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b2650","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1684\/ecn.2016.0371","article-title":"Clinical and cytokine profile evaluation in Northeast Brazilian psoriasis plaque-type patients","volume":"27","author":"Cardoso","year":"2016","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.humimm.2024.110814_b2655","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0923-1811(95)00384-5","article-title":"Increased spontaneous production of IL-8 in peripheral blood monocytes from the psoriatic patient: relation to focal infection and response to treatments","volume":"10","author":"Teranishi","year":"1995","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2660","first-page":"867","article-title":"Is there any correlation between the total number of neutrophils in plasma and concentration of interleukin-8 in psoriatic patients?","volume":"6","author":"Pietrzak","year":"2000","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.humimm.2024.110814_b2665","first-page":"261","article-title":"Plasma level of IL-8 in patients with psoriasis and its correlation with psoriasis area and severity index and the clinical type of the disease","volume":"55","author":"Pietrzak","year":"2000","journal-title":"Ann. Univ. Mariae Curie Sklodowska Med."},{"key":"10.1016\/j.humimm.2024.110814_b2670","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2249.1995.tb05525.x","article-title":"IL-8\/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy","volume":"99","author":"Lemster","year":"1995","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2675","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1023\/A:1022354212121","article-title":"Neutrophil functions and IL-8 in psoriatic arthritis and in cutaneous psoriasis","volume":"22","author":"Biasi","year":"1998","journal-title":"Inflammation"},{"key":"10.1016\/j.humimm.2024.110814_b2680","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/1523-1747.ep12514689","article-title":"Localization of neutrophil-activating peptide-1\/interleukin-8-immunoreactivity in normal and psoriatic skin","volume":"96","author":"Sticherling","year":"1991","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2685","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3892\/ijmm.2020.4771","article-title":"Transcriptomic landscaping of core genes and pathways of mild and severe psoriasis vulgaris","volume":"47","author":"Choudhary","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.humimm.2024.110814_b2690","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/archderm.1993.01680220086020","article-title":"Quantification of chemotactic peptides (C5a anaphylatoxin and IL-8) in psoriatic lesional skin","volume":"129","author":"Takematsu","year":"1993","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2695","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1749-6632.1993.tb35925.x","article-title":"Increased levels of leukotriene B4 and interleukin-8 in psoriatic skin","volume":"685","author":"Degiulio","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2700","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2340\/0001555572334336","article-title":"Interleukin-8 receptors in normal and psoriatic polymorphonuclear leukocytes","volume":"72","author":"Arenberger","year":"1992","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b2705","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.4049\/jimmunol.151.8.4399","article-title":"Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro","volume":"151","author":"Schulz","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2710","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s004030050218","article-title":"The expression of interleukin-8 receptor in untreated and treated psoriasis","volume":"289","author":"Beljaards","year":"1997","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b2715","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000087019","article-title":"Localization of IL-8 and complement components in lesional skin of psoriasis vulgaris and pustulosis palmaris et plantaris","volume":"211","author":"Ozawa","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.humimm.2024.110814_b2720","first-page":"129","article-title":"Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis","volume":"138","author":"Nickoloff","year":"1991","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.humimm.2024.110814_b2725","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/1523-1747.ep12495817","article-title":"Interleukin-8 immunoreactivity in the skin of healthy subjects and patients with palmoplantar pustulosis and psoriasis","volume":"98","author":"Anttila","year":"1992","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2730","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/1523-1747.ep12556058","article-title":"Neutrophil-activating proteins in psoriasis","volume":"98","author":"Schroder","year":"1992","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2735","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/1523-1747.ep12478128","article-title":"Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1\/IL-8 mRNA in situ","volume":"97","author":"Gillitzer","year":"1991","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2740","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0923-1811(00)00167-5","article-title":"Interleukin-8-positive neutrophils in psoriasis","volume":"26","author":"Duan","year":"2001","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2745","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2478\/v10039-010-0037-0","article-title":"IL-8, IL-12 and IL-10 cytokines generation by neutrophils, fibroblasts and neutrophils- fibroblasts interaction in psoriasis","volume":"55","author":"Glowacka","year":"2010","journal-title":"Adv. Med. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2750","first-page":"251","article-title":"Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules","volume":"15","author":"Koczan","year":"2005","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2755","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1067\/mai.2001.114707","article-title":"Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines","volume":"107","author":"Giustizieri","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2760","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/eji.201747017","article-title":"Bcl-3 induced by IL-22 via STAT3 activation acts as a potentiator of psoriasis-related gene expression in epidermal keratinocytes","volume":"48","author":"Tohyama","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2765","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1084\/jem.184.5.2007","article-title":"A proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes","volume":"184","author":"Bruch-Gerharz","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.humimm.2024.110814_b2770","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2230.1995.tb01274.x","article-title":"Vascular proliferation and angiogenic factors in psoriasis","volume":"20","author":"Creamer","year":"1995","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2775","doi-asserted-by":"crossref","first-page":"e0165577","DOI":"10.1371\/journal.pone.0165577","article-title":"Assessment of Interleukin 16 serum levels and skin expression in psoriasis patients in correlation with clinical severity of the disease","volume":"11","author":"Purzycka-Bohdan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.humimm.2024.110814_b2780","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jdermsci.2016.11.011","article-title":"Decreased expression of IL-27 in moderate-to-severe psoriasis and its anti-inflammation role in imiquimod-induced psoriasis-like mouse model","volume":"85","author":"Chen","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2785","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/jid.2009.349","article-title":"Possible roles of IL-27 in the pathogenesis of psoriasis","volume":"130","author":"Shibata","year":"2010","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2790","doi-asserted-by":"crossref","first-page":"843","DOI":"10.25259\/IJDVL_243_2021","article-title":"Interleukin 27 in psoriasis: Friend or foe?","volume":"88","author":"El-Komy","year":"2022","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"10.1016\/j.humimm.2024.110814_b2795","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/jid.2012.313","article-title":"IL-27 activates Th1-mediated responses in imiquimod-induced psoriasis-like skin lesions","volume":"133","author":"Shibata","year":"2013","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2800","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.abd.2020.11.007","article-title":"Enhanced serum interferon-lambda 1 interleukin-29 levels in patients with psoriasis vulgaris","volume":"96","author":"Fu","year":"2021","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2805","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006245","article-title":"IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis","volume":"5","author":"Wolk","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.humimm.2024.110814_b2810","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211004039","article-title":"Serum interleukin-30 level in patients with psoriasis and its correlation with psoriasis severity: a case-control study","volume":"49","author":"Omar","year":"2021","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.humimm.2024.110814_b2815","doi-asserted-by":"crossref","first-page":"61","DOI":"10.55133\/eji.310207","article-title":"Association of serum IL-30 and soluble GP130 with the risk of psoriasis vulgaris","volume":"31","author":"Shehata","year":"2024","journal-title":"Egypt. J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2820","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bbrc.2021.09.042","article-title":"IL-30 ameliorates imiquimod and K14-VEGF induced psoriasis-like disease by inhibiting both innate and adaptive immunity disorders","volume":"579","author":"Liu","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.humimm.2024.110814_b2825","first-page":"29","article-title":"Functional role of human interleukin-32 and nuclear transcription factor-kB in patients with psoriasis and psoriatic arthritis","volume":"12","author":"Al-Shobaili","year":"2018","journal-title":"Int J Health Sci (Qassim)"},{"key":"10.1016\/j.humimm.2024.110814_b2830","doi-asserted-by":"crossref","DOI":"10.3390\/diseases6010021","article-title":"Elevated Gene Expression of Interleukin-32 Isoforms Alpha, Beta, Gamma, and Delta in the Peripheral Blood of Chronic Psoriatic Patients","volume":"6","author":"Al-Shobaili","year":"2018","journal-title":"Diseases"},{"key":"10.1016\/j.humimm.2024.110814_b2835","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.jid.2023.05.023","article-title":"IL-34 Exerts Anti-Inflammatory Activities on Keratinocytes and Is Downregulated in Psoriatic-Inflamed Skin","volume":"143","author":"Croquette","year":"2023","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2840","doi-asserted-by":"crossref","DOI":"10.1111\/1348-0421.12605","article-title":"Clinical significance of decreased interleukin-35 expression in patients with psoriasis","author":"Li","year":"2018","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2845","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.4049\/jimmunol.2000346","article-title":"Correction: IL-35 decelerates the inflammatory process by regulating inflammatory cytokine secretion and M1\/M2 macrophage ratio in psoriasis","volume":"204","author":"Zhang","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2850","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/jcmm.13428","article-title":"IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells","volume":"22","author":"Wang","year":"2018","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.humimm.2024.110814_b2855","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.4049\/jimmunol.1600446","article-title":"IL-35 decelerates the inflammatory process by regulating inflammatory cytokine secretion and M1\/M2 macrophage ratio in psoriasis","volume":"197","author":"Zhang","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b2860","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2340\/00015555-70500502","article-title":"Lack of increase in granulocyte colony-stimulating factor in psoriatic skin","volume":"70","author":"Takematsu","year":"1990","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.humimm.2024.110814_b2865","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/jnci\/89.17.1315","article-title":"Worsening psoriasis after treatment with G-CSF in a patient with small-cell lung cancer","volume":"89","author":"Feliu","year":"1997","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.humimm.2024.110814_b2870","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3346\/jkms.1998.13.6.685","article-title":"Psoriasiform eruption triggered by recombinant granulocyte-macrophage colony stimulating factor (rGM-CSF) and exacerbated by granulocyte colony stimulating factor (rG-CSF) in a patient with breast cancer","volume":"13","author":"Cho","year":"1998","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2875","first-page":"438","article-title":"Induction of psoriasis by human recombinant granulocyte colony stimulating factor in a patient with small cell lung cancer","volume":"39","author":"Yonei","year":"2001","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"10.1016\/j.humimm.2024.110814_b2880","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.0906-6705.2004.00190.x","article-title":"Granulocyte colony-stimulating-factor-induced psoriasiform dermatitis resembles psoriasis with regard to abnormal cytokine expression and epidermal activation","volume":"13","author":"Mossner","year":"2004","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2885","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/0377-4929.94857","article-title":"Immunohistochemical study of osteopontin, Ki-67, and CD34 of psoriasis in Mansoura","volume":"55","author":"Amin","year":"2012","journal-title":"Egypt. Indian J Pathol Microbiol"},{"key":"10.1016\/j.humimm.2024.110814_b2890","article-title":"Dysregulation of connexin expression plays a pivotal role in psoriasis","volume":"22","author":"O'Shaughnessy","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2895","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jdermsci.2009.12.006","article-title":"Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis","volume":"57","author":"Henno","year":"2010","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b2900","doi-asserted-by":"crossref","unstructured":"J. Bhawan, C. Bansal, K. Whren, U. Schwertschlag, Group ILPS. K16 expression in uninvolved psoriatic skin: a possible marker of pre-clinical psoriasis. J. Cutan Pathol. 31 (2004) 471.","DOI":"10.1111\/j.0303-6987.2004.0220.x"},{"key":"10.1016\/j.humimm.2024.110814_b2905","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000247852","article-title":"Granulocyte-macrophage colony-stimulating factor in psoriasis","volume":"181","author":"Takematsu","year":"1990","journal-title":"Dermatologica"},{"key":"10.1016\/j.humimm.2024.110814_b2910","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0954-6111(95)90256-2","article-title":"Necrotizing vasculitis and exacerbation of psoriasis after granulocyte colony-stimulating factor for small cell lung carcinoma","volume":"89","author":"Couderc","year":"1995","journal-title":"Respir. Med."},{"key":"10.1016\/j.humimm.2024.110814_b2915","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0190-9622(08)81909-3","article-title":"Granulocyte-macrophage colony-stimulating factor and psoriasis","volume":"30","author":"Kelly","year":"1994","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2920","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2133.1993.tb00218.x","article-title":"Exacerbation of psoriasis with GM-CSF therapy","volume":"128","author":"Kelly","year":"1993","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2925","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1111\/1346-8138.16862","article-title":"Exacerbation of generalized pustular psoriasis after administration of granulocyte colony-stimulating factor in a patient with intravascular large B-cell lymphoma","volume":"50","author":"Sakashita","year":"2023","journal-title":"J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2930","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5021\/ad.2017.29.2.232","article-title":"Granulocyte colony-stimulating factor-induced psoriasiform dermatitis improved by narrowband ultraviolet B","volume":"29","author":"Jang","year":"2017","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2935","first-page":"567","article-title":"Flare of psoriasis and psoriatic arthritis following treatment with granulocyte colony-stimulating factor","volume":"101","author":"Kavanaugh","year":"1996","journal-title":"Am. J. Med."},{"key":"10.1016\/j.humimm.2024.110814_b2940","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/bjd.17195","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody","volume":"180","author":"Papp","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2945","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/bjd.17912","article-title":"Targeting granulocyte-monocyte colony-stimulating factor in psoriasis. What a negative study can teach us","volume":"180","author":"Crowley","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.humimm.2024.110814_b2950","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0190-9622(08)80879-1","article-title":"Clearance of unremitting psoriasis after treatment with granulocyte-macrophage colony-stimulating factor","volume":"27","author":"Raychaudhuri","year":"1992","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2955","doi-asserted-by":"crossref","first-page":"e0182646","DOI":"10.1371\/journal.pone.0182646","article-title":"GM-CSF in murine psoriasiform dermatitis: Redundant and pathogenic roles uncovered by antibody-induced neutralization and genetic deficiency","volume":"12","author":"Scholz","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.humimm.2024.110814_b2960","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1111\/1523-1747.ep12505653","article-title":"Growth factor and proto-oncogene expression in psoriasis","volume":"95","author":"Elder","year":"1990","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2965","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/BF03187327","article-title":"Immunohistochemical localization of transforming growth factor-alpha and epithelial growth factor receptor in human fetal developing skin, psoriasis and restrictive dermopathy","volume":"6","author":"Sergi","year":"2000","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b2970","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1346-8138.1991.tb03053.x","article-title":"Increased production of transforming growth factor-alpha in psoriatic epidermis","volume":"18","author":"Higashiyama","year":"1991","journal-title":"J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2975","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/1523-1747.ep12478077","article-title":"Localization of elevated transforming growth factor-alpha in psoriatic epidermis","volume":"95","author":"Turbitt","year":"1990","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2980","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.2916128","article-title":"Overexpression of transforming growth factor alpha in psoriatic epidermis","volume":"243","author":"Elder","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.humimm.2024.110814_b2985","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1365-2230.2008.03026.x","article-title":"Serum levels of transforming growth factor-beta1 in patients with mild psoriasis vulgaris and effect of treatment with biological drugs","volume":"34","author":"Kallimanis","year":"2009","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b2990","first-page":"2","article-title":"Serum concentrations of transforming growth factor beta 1 in patients with psoriasis vulgaris","volume":"12","author":"Nockowski","year":"2004","journal-title":"Acta Dermatovenerol. Croat."},{"key":"10.1016\/j.humimm.2024.110814_b2995","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/jcla.21717","article-title":"Serum vascular endothelial growth factor, transforming growth factor beta1, and nitric oxide levels in patients with psoriasis vulgaris: their correlation to disease severity","volume":"28","author":"Meki","year":"2014","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.humimm.2024.110814_b3000","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1468-3083.2008.03064.x","article-title":"MH EL-K, El-Tawdi A, Fawzi M, Kadry D: Serum and tissue expression of transforming growth factor beta 1 in psoriasis","volume":"23","author":"Zaher","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b3005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1006\/cyto.2002.1953","article-title":"Association between psoriasis severity and transforming growth factor beta(1) and beta (2) in plasma and scales from psoriatic lesions","volume":"19","author":"Flisiak","year":"2002","journal-title":"Cytokine"},{"key":"10.1016\/j.humimm.2024.110814_b3010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0923-1811(03)00107-5","article-title":"Downregulation of TGFbeta isoforms and their receptors contributes to keratinocyte hyperproliferation in psoriasis vulgaris","volume":"33","author":"Doi","year":"2003","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b3015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1365-2133.1998.02026.x","article-title":"Down-regulation of transforming growth factor-beta receptors I and II is seen in lesional but not non-lesional psoriatic epidermis","volume":"138","author":"Leivo","year":"1998","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b3020","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1600-0625.1993.tb00037.x","article-title":"Normal response to tumor necrosis factor-alpha and transforming growth factor-beta by keratinocytes in psoriasis","volume":"2","author":"Malkani","year":"1993","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b3025","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.jid.2017.06.005","article-title":"TGFbeta\/SMAD\/microRNA-486-3p Signaling Axis Mediates Keratin 17 Expression and Keratinocyte Hyperproliferation in Psoriasis","volume":"137","author":"Jiang","year":"2017","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b3030","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/1440-1681.12294","article-title":"Transforming growth factor-beta1 mediates psoriasis-like lesions via a Smad3-dependent mechanism in mice","volume":"41","author":"Zhang","year":"2014","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.humimm.2024.110814_b3035","article-title":"Transforming growth factor-beta in psoriasis. Pathogenesis and therapy","author":"Elder","year":"1990593218","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.humimm.2024.110814_b3040","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/BF00372708","article-title":"Organ culture of psoriatic skin: effect of TGF-alpha and TGF-beta on epidermal structure in vitro","volume":"284","author":"Kondo","year":"1992","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b3045","first-page":"115","article-title":"Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis","volume":"11","author":"Mussi","year":"1997","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.humimm.2024.110814_b3050","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19148723","article-title":"Changes in Tumor Necrosis Factor alpha (TNFalpha) and Peptidyl Arginine Deiminase 4 (PAD-4) Levels in Serum of General Treated Psoriatic Patients","volume":"19","author":"Czerwinska","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.humimm.2024.110814_b3055","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5455\/msm.2022.33.40-43","article-title":"Serum Levels of Tumor Necrosis Factor - alpha in Patients With Psoriasis","volume":"34","author":"Ovcina-Kurtovic","year":"2022","journal-title":"Mater Sociomed"},{"key":"10.1016\/j.humimm.2024.110814_b3060","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1468-3083.2005.01268.x","article-title":"Soluble TNF-receptors, naive CD31+ T cells and B-1a cells in psoriatic patients","volume":"19","author":"Chernyshov","year":"2005","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.humimm.2024.110814_b3065","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/508178","article-title":"Serum levels of TNF- alpha, IL-12\/23 p40, and IL-17 in psoriatic patients with and without nail psoriasis: a cross-sectional study","volume":"2014","author":"Kyriakou","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.humimm.2024.110814_b3070","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/1346-8138.15422","article-title":"Circulating tumor necrosis factor-alpha DNA are elevated in psoriasis","volume":"47","author":"Sakamoto","year":"2020","journal-title":"J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b3075","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/BF00455324","article-title":"Absence of tumor necrosis factor-alpha in suction blister fluids and stratum corneum from patients with psoriasis","volume":"281","author":"Takematsu","year":"1989","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.humimm.2024.110814_b3080","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s004030050317","article-title":"Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-alpha and their degranulation is associated with expression of ICAM-1 in the epidermis","volume":"290","author":"Ackermann","year":"1998","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b3085","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.1990.tb07279.x","article-title":"Immunomodulating cytokines in atopic dermatitis and psoriasis: production of tumour necrosis factor and lymphotoxin by mononuclear cells in vitro","volume":"122","author":"Kapp","year":"1990","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b3090","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0190-9622(91)70112-F","article-title":"Response to tumor necrosis factor in two cases of psoriasis","volume":"24","author":"Creaven","year":"1991","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.humimm.2024.110814_b3095","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/BF00402623","article-title":"Effect of tumour necrosis factor in the mouse-tail model of psoriasis","volume":"282","author":"Nagano","year":"1990","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.humimm.2024.110814_b3100","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.4049\/jimmunol.175.4.2721","article-title":"TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques","volume":"175","author":"Gottlieb","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2024.110814_b3105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/039463200601900204","article-title":"Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R P60 in psoriatic skin is driven by TNF-alpha","volume":"19","author":"Ogilvie","year":"2006","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.humimm.2024.110814_b3110","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ajpath.2013.04.021","article-title":"Inhibition of CCR7\/CCL19 axis in lesional skin is a critical event for clinical remission induced by TNF blockade in patients with psoriasis","volume":"183","author":"Bose","year":"2013","journal-title":"Am. J. Pathol."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924000740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924000740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T20:39:32Z","timestamp":1721939972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885924000740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":622,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0198885924000740"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2024.110814","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokines in psoriasis: From pathogenesis to targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2024.110814","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110814"}}